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Inflammatory Bowel Disease 
Inflammatory Bowel Disease (IBD) is a spectrum of chronic, episodic, inflammatory 
conditions of the gastrointestinal (GI) tract. IBD is conventionally divided into two 
main subtypes: Crohn’s disease (CD) and ulcerative colitis (UC). Both UC and CD 
can affect individuals of any age but they are mostly diagnosed in patients aged 
between 15 and 30 years. In the Western world, the number of new cases of IBD 
diagnosed each year (incidence rate) has been estimated to be about seven per 
100,000 (Ghosh et al., 2000), with over 200 people per 100,000 living with UC at 
any given time. Both UC and CD cause significant gastrointestinal symptoms, 
including abdominal pain and blood diarrhoea. IBD also is associated with a 
spectrum of extraintestinal manifestation, including liver and biliary disease, 
osteoporosis, eye inflammation, arthritis, ankylosing spondylitis, schlerosing 
cholangitis, pyoderma gangrenosum and erythema nodosum. 
Pathogenesis 
While CD and UC share a number of gastrointestinal and extraintestinal 
manifestations and can respond to similar array of drugs, emerging evidences suggest 
that they result from fundamentally distinct, pathogenic mechanisms (Bouma et 
Strober, 2003). Crohn’s disease may irregularly affect the entire GI tract, even 
though most commonly the small intestine and the area adjacent to the ileocecal 
valve. The inflammation in CD is not necessarily confluent and its transmural nature 
may lead to fibrosis and strictures or, alternatively, to fistulas formation. Conversely, 
UC is characterised by confluent mucosal inflammation of the colon starting at the 
anal verge and extending proximally for a variable extent (e.g. colitis, left-side 
colitis, pancolitis). From a histological point of view, the transmural lesions in 
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Chron’s disease exhibit marked infiltration of lymphocytes and macrophages, 
granuloma formation and submucosal fibrosis, whereas the superficial lesions in 
ulcerative colitis have lymphocytic and neutrophilic infiltrates. Within the diseased 
bowel in Crohn's disease, the cytokine profile includes increased levels of 
interleukin-12 (IL-12), interferon-γ, and tumor necrosis factor-α (TNF-α), findings 
characteristic of T-helper 1 (TH1)–mediated inflammatory processes. In contrast, the 
inflammatory response in ulcerative colitis resembles more closely that mediated by 
the TH2 pathway. In Figure 1, a summary of proposed pathogenic events of IBD and 
potential sites of therapeutic intervention are shown. 
 
Figure 1: Proposed pathogenesis of inflammatory bowel disease and target sites for pharmacological 
intervention. Adapted from Sellin et al., 2006. 
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The interactions among bacterial antigens in the intestinal lumen and immune cells in 
the intestinal wall is represented. If the endothelial barrier is impaired, bacterial 
antigens (dark circles) can gain access to antigen-presenting cells (APCs) in the 
lamina propria. APCs present, consequently, the antigen(s) to CD4+ lymphocytes 
and also secrete IL-12, thereby inducing the differentiation of TH1 cells in Crohn's 
disease (or type 2 helper T cells in ulcerative colitis). The TH1 cells produce a 
characteristic array of lymphokines, including IFN-α, which in turn activates 
macrophages. Macrophages positively regulate TH1 cells by secreting additional   
IL-12 and TNF- α. In addition to general immunosuppressants that affect multiple 
sites of inflammation (e.g. glucocorticoids, thioguanine derivatives, methotrexate, 
and cyclosporine), more specific sites for therapeutic intervention involve the 
intestinal bacteria (antibiotics and probiotics) and therapy directed at TNF-α. 
Aetiology 
The aetiology of IBD appears multifactorial: an underlying immune dysregulation 
coupled with an intolerance to gut flora seems fundamental to the pathogenesis that, 
in some cases, are associated with genetic mutations or are initiated by 
environmental factors. An inappropriate and excessive response to dietary triggers, 
unidentified infectious agents or the normal colonic bacterial population (Kovvali 
and Das, 2005) by an inadequately regulated mucosal immune system are thought to 
play a major pathophysiological role in the chronic inflammation and manifestation 
of symptoms of UC and CD. Various environmental and host factors (e.g. genetic-, 
epithelial-, immune and non-immune) are involved in the pathogenesis of IBD, even 
though the exact mechanism by which the intestinal mucosa loses tolerance to its 
bacterial neighbors remains elusive. In addition to environmental factors, genetic 
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predisposition, stronger in CD than in CD, also seems nowadays to play a key role in 
the pathology. The genetic aspect of research is quite focused on numerous 
chromosomal loci. Important insights into pathogenesis also have emerged from 
genetic analyses of CD.  
 
The role of host genetic regulation of the innate immune response in the pathogenesis 
of CD has been brought to sharp focus by the identification of a gene called 
nucleotide-binding oligomerization domain-2 (NOD2/CARD15). NOD2/CARD15 is 
an intracellular element responsible for the indirect recognition of bacterial 
peptidoglycan through the binding of muramyl dipeptide, thereby playing an 
important role in the natural immunity to bacterial pathogens (Hugot et al., 2001). 
Consistent with this model, other bacterial antigens have been identified. Dalwadi et 
al. (2001) and Lodes et al. (2004), identified pseudomonal protein I2 and a flagellin 
protein, respectively, as dominant superantigens that induce the TH1 response in 
Crohn's disease. Thus, these converging experimental approaches are generating new 
insights into the pathogenesis of Crohn's disease that soon may translate into novel 
therapeutic approaches to IBD. 
Pharmacotherapy 
Medical therapy for IBD is still problematic due to its multifactorial, polygenic 
nature. A part from a total proctocolectomy for UC, there is no cure for IBD. 
Because no unique abnormality has been identified, current therapy for IBD seeks to 
dampen the generalized inflammatory response; however, no agent can reliably 
accomplish this, and the response of an individual patient to a given medicine may be 
limited and unpredictable. Based on this variable response, clinical trials generally 
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employ standardized quantitative assessments of efficacy that take into account both 
clinical and laboratory parameters (e.g., the Crohn's Disease Activity Index). 
 
Current treatments are aimed at reducing the symptom burden, controlling acute 
exacerbations of the disease and maintaining the disease quiescence or treating 
specific complications, such as fistulas. Choice of therapy depends largely on the 
severity of the disease, and may also be influenced by such factors as disease 
location, side effects, as well as costs. Conventional steroids, such as glucocorticoids, 
remain the treatment of choice for moderate to severe flares, but they are neither 
effective at preventing  post-operative relapse (Bergman et al., 1976) nor appropriate 
for long-term use because of side effects and their inability to maintain remission. 
Conventional steroids are thereby reserved for patients who have failed more first-
line therapy. Non-systemic steroids, such as Budesonide have low systemic side 
effects owing to a high (80-90 %) first-pass metabolism (Kane et al., 2002) and are 
effective as first-line agent for ileal and/or right colonic and perianal disease 
although maintenance benefits remain to be proven. Immunomodulators, such as     
6-Mercaptopurine (6-MP) and its prodrug azathioprine (AZA), are preferred for 
long-term management, but they require several weeks to achieve their therapeutic 
effect have therefore a limited role in the acute setting. Cyclosporine and Tacrolimus, 
macrolide antibiotics, are used primarily to prevent allograft rejection in the 
transplant setting and can be effective for severe or refractory UC.  
A more thorough appreciation of the intricacies of the inflammatory response and 
improved biotechnology have led to the development of biological agents that can 
target single steps in the immune cascade. For example Adalimumab (D2E7, 
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Humira®; Abbott Laboratories, Chicago, IL) is a subcutaneously administered 
recombinant of human IgG1 monoclonal antibody that  binds with high specificity and 
affinity to human TNF-α and consists of human-derived heavy and light chain 
variable regions and human IgG1 constant region. Analogously, Certoluximab pegol 
(UCB; Smyrna, GA) is a monoclonal humanized anti TNF-α antibody Fab’ fragment 
linked chemically to polyethylene glycol (PEG). Anti-TNF agents have been 
effective for patients with moderate to severe UC and CD, independent of 
concomitant medications. 
However, potential side effects, costs and immunogenicity remain critical issues 
relating to current and future biological agents. 
 
Drug delivery to the appropriate site(s) along the gastrointestinal tract also has been a 
major challenge, and second-generation devices have been developed to improve 
pharmacokinetic profiles, thus increasing efficacy and decreasing side-effects. 
 
5-ASA (mesalamine)-based therapy 
 
Mechanism of action and pharmacological properties 
The current standard of care for mild-to-moderate UC and CD, with demonstrated 
efficacy and safety, involves 5-aminosalicylic acid (5-ASA, mesalamine) (Sutherland 
et al., 2003). The parent compound of 5-ASA is sulfasalazine (SP), which consists of 
a 5-ASA molecule linked, by an azo-bond, to a sulfapyridine moiety. Sulfasalazine 
was developed originally as therapy for rheumatoid arthritis, but clinical trials 
serendipitously demonstrated a beneficial effect on the gastrointestinal symptoms of 
subjects with concomitant ulcerative colitis. SP was for many years the standard 
   Introduction 
__________________________________________________________________________________ 
 7 
therapy after pivotal introduction of remission and maintenance trials in the 1960 
(Baron et al., 1962). However, up to one-third of patients were intolerant of 
sulfasalazine with the most common adverse effects being nausea, dyspepsia, 
malaise or headaches. Less common effects were dyscrasias, male infertility and skin 
rashes. These adverse events were demonstrated to be arisen to the sulfapyridine 
moiety after it was recognised, in 1977, that the therapeutic effect of SP is due to the 
release of the 5-ASA moiety into the lumen by the action of colonic azo-reductase in 
the distal ileum and colon (Azad et al., 1977). The diazo linkage in sulfasalazine 
prevents absorption in stomach and small intestine of both sulfapyridine and 5-ASA, 
that would be otherwise absorbed in the upper gastrointestinal tract when given 
individually. The therapeutic moiety (5-ASA) is therefore liberated after cleavage of 
the diazo bond by colonic bacteria (Figure 2). 
 
 
Figure 2: Structures of sulfasalazine and related agents. Blue N atoms indicate the diazo linkage 
undergoing cleavage by colonic azo-reductase, to generate the active moiety. Adapted from Sellin et 
al., 2006. 
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In-vitro 5-ASA shares many of the pharmacological properties of the non-steroidal 
anti-inflammatory drugs (NSAIDs), including inhibition of cyclooxigenase, 
lipoxygenase, B-cells, and several key inflammatory cytokines. However, the 
therapeutic effect of 5-ASA does not appear to be related to cyclooxygenase 
inhibition; indeed, traditional NSAIDs actually may exacerbate IBD (Desreumax et 
al., 2006). 
 
A number of different but not mutually exclusive mechanisms have been proposed, 
including modulation of prostaglandin metabolism (Ligumsky et al., 1981), 
inhibition of intestinal epithelial cell injury and apoptosis induced by oxidative stress 
(De Allegri et al., 1990), inhibition of colonic production of chemo-attractant 
leukotrienes (Lauritsen et al., 1996), increase in the intestinal epithelial cell heat 
shock protein response (Burress et al., 1997) and inhibition of the activity of the 
nuclear factor-kappa B (NF-jB) pathway (Klotz et al., 2005). However, the key to an 
integrated understanding of the mechanism of action was the realization that 5-ASA 
can activate selective proxisome proliferators-activated receptor ligand-γ (PPAR- γ), 
a nuclear receptor that controls cell proliferation and apoptosis (Desreumax et al., 
2006). The anti-inflammatory actions of 5-ASA produce effects similar to activation 
of PPAR- γ, e.g. modulation of inflammatory cytokine production, leading to 
decreased transcriptional activity of NF-jB, and reduced synthesis of prostaglandins 
and leukotrienes (Kaiser et al., 1999). Activation of PPAR- γ also has anti-
tumourigenic effects which manifest as anti-proliferative activities, pro-
differentiation activities, pro-apoptotic activities, inhibition of the formation of 
aberrant crypts foci and inhibition of the development of colon tumours. PPAR-γ 
molecules are expressed at particularly high levels in the epithelium of the colon and 
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adipose tissue, at least an order of magnitude higher than in the small intestine 
(Figure 3). 
 
Figure 3: Expression of peroxisome proliferator-activated receptors (PPAR)- γ. Adapted from 
Desreumaux et al., 2002. 
 
Rousseaux et al. (2005) demonstrated that 5-ASA is able to bind PPAR-γ, to induce 
its translocation from the cytosol of epithelial cells to the nucleus, to promote a 
PPAR-γ conformational change, and to recruit a co-activator named DRIP, 
concluding that PPARγ is an essential receptor mediating the common 5-ASA 
activities in IBD. 
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Figure 4: Molecular mechanisms of peroxisome proliferator activated receptor γ (PPARγ) activation 
by 5-aminosalicylic acid (5-ASA). Adpated fro Dubuquoy et al., 2006. 
 
After local administration, 5-ASA crosses the cell membrane of the epithelial cell 
through a transporter and binds to PPARγ in the cytoplasm (Figure 4). 5-ASA then 
induces its nuclear translocation, promotes a PPARγ conformational change, and 
recruits the coactivator DRIP, leading to formation of a heterodimer between PPARγ 
and retinoid X receptor (RXR) and activation of the PPARγ response elements 
(PPRE). 
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5-ASA delivery strategies and limitations of current formulations 
 
The action of 5-ASA is demonstrated to be predominantly topical at the site of 
inflammation (Qureshi et al., 2005). A number of rectal and oral formulations have 
therefore been proposed, to achieve drug delivery to the target gastrointestinal tissue. 
Even though rectal preparations (e.g. suppositories, enemas and foams) are effective 
in the treatment of distal colitis, they are associated with several adverse events, 
including burning sensations as well as leakage, retention and bloating problems. 
Moreover, patients often dislike rectal formulations because of difficulty with this 
mode of administration and problems with discomfort (Segars et al., 1992). In 
addition, rectal preparations allow only the distal colon and rectum to be reached, 
being therefore ineffective in the treatment of proximal colitis and pancolitis 
(ulcerative colitis that involves the entire large intestine). When the inflammation 
spreads above the left flexure and during periods of remission, oral delivery of         
5-ASA is thereby needed.  
 
However, oral administration of 5-ASA presents a challenge as the majority of the 
drug, when administered as a conventional dosage form, is rapidly absorbed in the 
small intestine, leaving little or no 5-ASA to achieve the inflamed mucosa and 
perform its therapeutic activity. In fact, when administered orally, 5-ASA is nearly 
completely systemically absorbed from the proximal small intestine and then 
extensively metabolised, in intestinal epithelial cells and the liver, to N-acetyl-5-
ASA. 
In order to prevent unwanted systemic absorption, thus enhancing the clinic outcome 
and tolerability of the treatment, a number of strategies have been proposed. These 
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strategies include the use of conventional dosage forms, based on prodrugs, and Drug 
Delivery Systems (DDS) based on delayed- or prolonged-release formulations. 
A number of products have been initially developed based on 5-ASA prodrugs 
intended for activation by colonic bacteria.  
As discussed already, the parent compound is sulfasalazine, that consists of a 5-ASA 
molecule azo-bonded to a sulfapyridine moiety. Sulfasalazine largely resists gastric 
breakdown and systemic absorption and, when in the colon, undergoes cleavage of 
the sulphapyridine-5-ASA bond due to bacterial azoreductase. Sulfasalazine has been 
widely prescribed for the last four decades due to its effectiveness and low costs. 
However, it is associated with dose-dependent adverse events (e.g. head-ache, nausea 
and dyspepsia) related to the sulfapyridine moiety. Different prodrugs have therefore 
been proposed, e.g. Olsalazine (Dipentum; Celltech Pharmaceuticals, Inc., Rochester, 
NY, USA), which consists of two azo-bonded 5-ASA molecules, and Balsalazide 
(Colazal; Salix Pharmaceuticals, Inc., Morrisville, NC, USA), in which 5-ASA is 
linked to a benzoic acid (inert carrier) derivative.  
 
Prodrugs are effective in the treatment of ulcerative colitis but, since they largely by-
pass the small intestine, they do not have significant effect neither in small bowel 
Crohn’s disease nor in pancolitis.  
A second approach that has been made to maximise delivery of 5-ASA to the 
affected regions of the GI tract was the development of DDS, including delayed- or 
prolonged-release formulations. Most of the mesalamine-based products currently 
available on the market are delayed-release oral dosage forms. These involve the use 
of pH-dependent coating polymers (e.g. methacrylates-based polymers) that dissolve 
over a certain value of pH (generally 7, since it is thought to correspond to the pH 
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value of the human terminal ileum). The release performance of these delayed-
release formulation therefore rely on the hypothetical progressive raise of pH along 
the GI tract. Unfortunately, the endoluminal pH of patients affected by CD and UC is 
highly variable and it is demonstrated to fluctuate of 2-3 units (Fallingborg et al., 
1993), so that the pharmacokinetic profile and therapeutic effect of such products can 
be compromised. Delayed-release formulations include Asacol® (Procter & Gamble 
Pharmaceuticals, Cincinnati, OH, USA) and Salofalk® tablets (Axcan Pharma, Mont 
St Hilaire, QC, Canada). 
One of the latest approach for 5-ASA delivery is based on a prolonged-release 
formulation, marketed as Pentasa® (Shire US, Inc. Wayne, PA, USA). Pentasa®  
comprises 5-ASA granules enclosed within an ethylcellulose membrane, which 
allows pH-independent release of the drug to occur. These ethylcellulose-coated 
granules gradually release the active drug beginning in the stomach and continuing 
throughout the jejunum, the ileum and the colon to rectum, allowing therefore the 
entire intestine to be “covered” (Figure 6). This is the reason why Pentasa®  is often 
used “off label” to treat Crohn’s disease in addition to its indicated use in UC (Cohen 
et al., 2006). However, the main limitation of Pentasa®  is that a considerable extent 
of 5-ASA is released during the multiparticulates stay in the stomach. This would 
result in a relatively high loss of mesalamine due to systemic absorption occurring in 
the duodenum, and subsequently to less drug reaching inflamed tissues lower in the 
small intestine and in the colon (Klotz et al., 1985; Vree et al., 2001). 
In Figure 5, a scheme representing sites of release of different 5-ASA formulations is 
depicted. 
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Figure 5: Theoretical release profiles from different 5-ASA oral dosage forms. 
 
Oral dosage forms currently available on the market have several limitations. Firstly, 
prodrugs and delayed-release formulations are not equally effective in the treatment 
of both UC and CD as they may not deliver therapeutically effective doses of 5-ASA 
to the left side of the colon (a site affected in all patients with UC). Indeed, clinical 
studies have shown that mucosal 5-ASA concentrations using azo-bonded or 
delayed-release formulations are typically highest in the right-sided colon, whereas 
in the rectum the concentration of 5-ASA is much lower (Frieri et al., 1999). 
Secondly, it has thus far been necessary to dose these formulations multiple times 
daily. In fact, recent clinical trials convincingly demonstrated that by increasing the 
standard dosage regimen of 5-ASA up to 4.8 g/day, both safety and efficacy and 
hence cost-effectiveness of therapy can be improved, with no increase in adverse 
events (Buckland and Bodger, 2008). This has been considered essential to ensure 
that therapeutically effective 5-ASA concentrations are maintained in the affected 
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areas, and indeed, formulations dosed in this way have been shown to be efficacious 
for the treatment of UC in clinical studies (Carter et al., 2004).  
Most of the oral formulations currently available on the market contain a relatively 
low drug dosage (generally 500 mg 5-ASA/unit), in particular for prodrugs whose   
5-ASA content is always less than 300 mg/unit. Multiple daily administrations and a 
high number of capsules/tablets (up to 16 per day) are therefore required to meet the 
recommended 5-ASA dosage regimen. The inconvenience of frequent daily dosing, 
together with the number of capsules/tablets (pill burden) have been identified as key 
factors in reducing patient acceptability with therapy in UC and CD, leading to 
reduced drug efficacy and thus poorer disease control, i.e. an increased number of 
UC flares (Kane, 2007). 
The limitations of current oral and rectal formulations have driven the evolution of  
5-ASA therapeutics to ensure patient compliance as well as improve delivery of 
active drug to all affected areas of the colon. Recent developments include high-
strength tablet formulations aiming to reduce daily administrations and improving 
compliance and innovative formulations (multiple-units) offering more convenient 
dosing in addition to improved drug delivery to the whole colon. A novel, high 
strength (1.2 g 5-ASA/tablet) formulation, SPD476 marketed as LialdaTM in the US 
and Mezavant TM in the EU (otherwise known as MMX mesalamine; Shire 
Pharmaceuticals Inc., Wayne, PA, under license from Giuliani SpA, Milan, Italy) has 
been recently approved by the US Food and Drug Administration for the induction of 
remission in patients with active mild-to-moderate ulcerative colitis. MMX 
comprises a tablet, coated with a gastro-resistant pH-dependent polymer film that 
breaks down at pH ≥ 7, containing 1.2 g mesalamine embedded in a matrix, which is 
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claimed to disintegrate slowly over 24 h. Even though MMX mesalamine allows the 
pill burden to be reduced, thanks to the high dose of 5-ASA, it still relies on a pH-
dependent approach. 
Lately, 5-ASA multiple unit formulations, have been studied with the aim of 
providing less frequent dosing in an easy-to-swallow formulation (Raedler et al., 
2003). Multiple unit drug delivery systems are becoming more widespread. Provided 
as individual sachets containing a single dose, these formulations utilize granules to 
effect a delayed and sustained release of 5-ASA with similar delivery properties and 
systemic exposure to tablets (Lichtenstein et al., 2007). Salofalk® 500 mg and 1 g 
(Axcan Pharma and Falk Pharma, Freiburg, Germany) and Pentasa® 1 g (Ferring 
A/S) are currently available in some European markets. Phase III trials are 
continuing in the US and a 1.5 g, once daily encapsulated mesalamine micropellet 
formulation (Salofalk Granustix®) is also under clinical development (Salix 
Pharmaceuticals Inc., Morrisville, NC, USA). Several clinical studies have been 
performed to assess and compare the efficacy of mesalamine granules vs 
conventional tablets in healthy volunteers. In one study of 14 healthy male 
volunteers, mesalamine containing granules (500 mg) released 5-ASA in the same 
target region (ileo-ciecal) and in a comparable timeframe to mesalamine tablets 
(Salofalk, 500 mg; Dr Falk Pharma GmbH, Freiburg, Germany) under fasting 
conditions (Brunner et al., 2003). Pharmacokinetic analyses showed that the plasma 
under the curve vales were significantly lower for the granules than for the tablet 
formulation, suggesting a prolonged release of 5-ASA. The efficacy of mesalamine 
granules [1.5 d per sachet, taken twice daily (3g/day)] and tablets [2 x 500 mg 
tablets, three times daily] in patients with mild-to-moderate UC (n ¼ 362) have been 
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compared in a phase II, double-blind, active-controlled study (Raedler et al., 2004). 
The study was designed to show non-inferiority of the multiparticulate formulation to 
tablets in terms of clinical remission within 8 weeks. Clinical remission was achieved 
by 67% of patients who received the multiparticulate formulation compared with 
62.9% of patients who received the tablet formulation, supporting the non-inferiority 
of the granule formulation (OR 1.199; 95% CI: 0.758– 1.897). The effects of 
mesalamine prolonged-release granules [one packet four times daily or two packets 
twice daily (4 g/day), Pentasa® Sachet] has also been compared with prolonged- 
release mesalamine tablets [2 x 500 mg four times daily (4 g/day), Pentasa] in 227 
patients with mild-to-moderate UC. Once again, the study was designed to confirm 
the non-inferiority of the multiparticulte formulation compared with the standard 
tablet. 
 
Even though current mesalamine-based products have proven their efficacy and 
safety in the treatment of IBD, both patient acceptability and the clinical outcome 
might be improved. 
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Inflammatory bowel disease (IBD) is a group of chronic, inflammatory conditions of 
the gastrointestinal (GI) tract. IBD is conventionally divided into two major 
subtypes, i.e. Crohn’s disease (CD) and ulcerative colitis (UC). As the name 
suggests, UC mainly affect the colonic region, even though it may extend proximally 
(e.g. colitis, left-side colitis and pancolitis). Conversely, the small intestine and/or the 
ileocolonic area are involved in CD.  
The first-line drug therapy for mild-to-moderate acute exacerbations of UC and, 
occasionally of CD, is based on the use of 5-aminosalicylic acid (5-ASA, 
mesalamine). 
Since the anti-inflammatory action of 5-ASA is thought to be predominantly topical 
at the site of inflammation, formulation strategies able to deliver the API to the 
targeted areas of the GI tract are needed. Current oral approaches are based on the 
use of prodrugs (selectively activated by colonic bacteria) and drug delivery systems 
(DDS) that enable a delayed- or prolonged-release of the drug. 
 
Most of the mesalamine-based products, currently available on the market, are 
associated with a number of limitations. Both prodrugs and delayed-release systems 
are, in fact, not equally effective in the treatment of UC and CD, as most of the 
therapeutically effective dose of 5-ASA is delivered to the distal areas of the large 
intestine, thus leaving the proximal small intestine (which is, as stated, an area 
commonly affected by CD) potentially untreated. Moreover, delayed-release 
formulations rely on the hypothetical progressive raise of pH along the GI tract. This 
might represent an important limitation, considered the high variability of this 
physiological parameter, in particular in subjects suffering of IBD (Haddish-Berhane 
et al., 2006). 
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On the other hand, prolonged-release formulations should allow a slow and pH-
independent release of 5-ASA throughout the entire intestine to occur, thus 
potentially meet the overall IBD needs. However, a considerable extent of 5-ASA is 
released by these formulations, already in the stomach. This would result in a 
relatively high loss of mesalamine, due to considerable systemic absorption 
occurring in the duodenum, and subsequently to less drug reaching inflamed tissues 
lower in the small intestine and/or in the large bowel.  
An other important limitation, common to most of the mesalamine-based 
preparations currently available on the market, is the drug dose (500 mg                   
5-ASA/unit), relatively low. If considering the complex IBD dosing regimen of 2.4-
4.8 g/day, multiple daily administration are therefore required, thus reducing patient 
acceptability and potentially impairing the therapy.  
 
On the basis of the above premises, the aim of the research project has been the 
development of a multiple-unit oral dosage form, containing a high dose (> 1,000 
mg) of 5-ASA, in order to achieve a once/twice-a-day administration, improving 
compliance. Moreover, this formulation is intended to prevent/minimise gastric 
breakdown and allow a slow and pH-independent release of 5-ASA, throughout the 
entire intestine, to occur. Multiparticulates, based on high density pellets, have been 
sought as promising alternatives for the administration of 5-ASA, both for their 
biopharmaceutical (e.g. more even and predictable distribution and transit in the GI 
tract) and technological (e.g. high drug loading and bulk density) advantages. 
The overall project has been structured into three stages:  
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1) Development of a multiple-unit drug containing core, based on highly loaded 
5-ASA pellets [chapter 1]. 
2) Assessment of the scale-up ability of the promising highly-loaded multiple-
unit formulation [chapter 2]. 
3) Tailoring of drug release accordingly to specific IBD therapeutic needs, and 
proposal of a high strength multiple-unit drug delivery system (DDS) 
[chapter 3]. 
 
[Chapter 1] Firstly, the feasibility of producing a multiparticulate core based on 
highly-loaded (> 90wt%) 5-ASA pellets needed to be assessed. Extrusion-
spheronisation (E-S) was investigated as the manufacturing technique, as it offers the 
potential to produce pellets with high drug load and density.  
A ram extruder apparatus (capillary rheometer) was initially employed to investigate, 
systematically, the rheological behavior of highly-loaded 5-ASA pastes undergoing 
extrusion. In particular, the effect of the chemical (acidity) and physical (particle size 
and shape) characteristics of 5-ASA were studied. The influence of the E-S aid in the 
processing of highly-loaded 5-ASA pastes, was also assessed. The water retention 
ability, quantified by centrifuge testing and supported by ram extrusion, as well as 
the rheological performance of a standard microcrystalline cellulose (MCC) grade 
(i.e. Avicel PH101) and colloidal ones (i.e. Avicel RC591 and CL611) containing 
sodium carboxymethylcellulose were therefore investigated. Moreover, ram 
extrusion of solid-liquid paste formulations through multi-holed square-ended dies 
was used to assess the extrudability of different 5-ASA/MCC paste formulations. 
Extrudates were spheronised using a bench-top device (Caleva) and the quality of 
extrudates monitored via visual and automated shape analyses. 
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The research activity pertaining to the rheological studies and feasibility of 
processing highly-loaded 5-ASA paste formulations was performed at the 
“Department of Chemical Engineering and Biotechnology” of the University of 
Cambridge (UK) and it was item for publication (Di Pretoro et al., 2010) 
 
[Chapter 2] Being our next objective, the realization of an industrial scalable 
multiple-unit dosage form, a feasibility study on the scale-up ability of both the 
milling and the E-S processes was performed. Firstly, in collaboration with a 
company specialised in milling processes (IMS Micronizzazioni S.p.A., Milano, 
Italy) we investigated the possibility of reproducing, by an industrial scale 
microniser, a batch of 5-ASA with similar physical characteristics to those obtained 
via a bench-scale apparatus (planetary ball-mill).  
Afterwards we investigated the feasibility of transferring a promising highly-loaded 
5-ASA multi-particulate formulation, previously identified in the ram extruder, to a 
pilot-scale equipment (basket extruder, Nica®). Considered the complexity and 
multifactoriality of the E-S process, a factorial approach, namely a mixed fractional 
factorial design (MFFD), aiming to identify both the process and formulation 
parameters that affect mostly the E-S process of highly-loaded 5-ASA paste 
formulations, was carried out. In particular, the effect of three formulation 
components (5-ASA:MCC ratio, water and an extra binder amounts) and two process 
parameters (extrusion speed and spheronisation time) on the process yield and on the 
final properties of the pellets (i.e. size, shape, mechanical resistance, bulk density and 
dissolution properties), was investigated. The independent variables and the relevant 
experimental space investigated were selected on the base of preliminary trials.  
   Aim of the project 
__________________________________________________________________________________ 
 25 
27 runs, including 3 replicates of the central point, were performed. An optimisation 
study, based on the desirability function approach, was finally undertaken to identify 
the combination of factors that would provide the optimal response values to be 
obtained. 
 
[Chapter 3] The drug release of highly-loaded 5-ASA pellets was accordingly 
tailored to meet specific IBD therapeutic needs. To achieve modular sustained- and 
pH-independent release profiles, pellets were coated with a polyvinyl acetate 
polymeric dispersion, up to different theoretical weight gains. An outer, additional, 
acrylate polymeric layer was applied to avoid/minimise 5-ASA loss from pellets 
during the gastric residence time. Coating process was performed in an pilot-scale 
fluidized bed apparatus (Glatt® Process Technology GmbH, Binzen, Germany). 
Once the optimal coating levels were identified, preliminary attempts to develop a 
final DDS in the dosage form of capsules, containing more than 1,000 mg API were 
also made. 
 
The in-vitro drug release performance of the final DDS was finally tested and 
compared to that of two commercially available products, namely a high strength 
single-unit DDS (LialdaTM tablets, 1,200 mg 5-ASA) and a multiple-unit dosage 
form (Pentasa® capsules, 500 mg 5-ASA). 
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EXTRUSIO-SPHEROISATIO OF HIGHLY-LOADED 5-ASA 
MULTIPARTICULATE DOSAGE FORMS 
 
G. Di Pretoro, L. Zema, A. Gazzaniga, S.L. Rough, D.I. Wilson. Extrusion-spheronisation of highly-
loaded 5-ASA multiparticulate dosage forms. Int. J. Pharm. 402 (2010) 153-164. 
 
Abstract 
 
The aim of the current work was to develop an extrusion-spheronisation (E-S) route 
to manufacture pellets with a high loading (≥ 90 wt%) of 5-aminosalicylic acid       
(5-ASA). Ram extrusion studies, supported by centrifuge testing, were employed to 
investigate the effect of the chemical (acidity) and physical (particle size and shape) 
characteristics of 5-ASA on the ability of microcrystalline cellulose (MCC)-based 
pastes to retain water when subjected to pressure. Liquid phase migration (LPM) 
within the paste during the extrusion, and hence variation in water content of 
extrudates and reproducibility of the final E-S product, was generally observed. The 
extent of LPM was found to be related to both the drug loading and its physical 
properties, most notably the particle shape (needle-like). A reduction in particle size, 
combined with a change in the shape of the 5-ASA particles, allowed LPM to be 
reduced considerably or eliminated. The performance of colloidal grades of MCC 
(Avicel RC591 and CL611) as alternative extrusion aids to the standard Avicel 
PH101 was also investigated: these proved to be superior aids for the highly-loaded 
5-ASA pastes as their greater water retention capacity mitigated LPM. Combining 
these results yielded a route for manufacturing pellets with 5-ASA loading ≥ 90 wt%. 
 
Keywords: 5-aminosalicylic acid; ram extrusion; liquid phase migration; 
microcrystalline cellulose; granulation 
Extrusion-spheronisation of highly-loaded 5-ASA multiparticulate dosage forms  CHAPTER 1 
__________________________________________________________________________________ 
 27 
1. ITRODUCTIO 
 
5-ASA treatment requirements  
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic, episodic inflammatory 
conditions of the gastro-intestinal tract, which primarily affect the ileum and the 
colon, respectively (Cohen, 2006). The first-line drug therapy for mild to moderate 
acute exacerbations of CD and UC is, at present, based on 5-aminosalicylic acid     
(5-ASA, mesalamine). Since the anti-inflammatory action of 5-ASA is thought to be 
predominantly topical at the site of inflammation, oral modified-release delivery 
systems (e.g. enteric coated products) are generally employed to maximise drug 
delivery to the affected regions while minimising systemic absorption. 5-ASA is 
generally administered at the dosage regimen of 2.4 g/day, even though recent 
clinical trials have convincingly demonstrated that by doubling the standard dose of 
mesalamine, both safety and efficacy and hence cost-effectiveness can be improved, 
with no increase in adverse events (Buckland and Bodger, 2008). However, most of 
the oral formulations currently available on the market are associated with a number 
of limitations, mainly a relatively low drug dosage (generally 500 mg 5-ASA/unit). 
Frequent daily dosing and a high number of tablets/capsules are therefore required 
for the treatment of CD and UC, at the expense of patient acceptability and 
adherence to therapy (Cervený et al., 2007).  
 
To improve compliance, a high strength solid formulation containing more than 1 g 
5-ASA/unit would be of interest, allowing once/twice daily administrations to be 
achieved. Multi-particulate dosage forms, based on high density pellets, have been 
sought as promising alternatives for the administration of 5-ASA, both for their 
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biopharmaceutical (e.g. more even and predictable distribution and transportation in 
the gastro-intestinal tract) and technological (e.g. high drug loading) advantages 
(Bechgaard and Hagermann, 1978). Extrusion-spheronisation (E-S) was investigated 
as the manufacturing technique in the present work, as it offers the potential to 
produce highly-loaded pellets (Gazzaniga et al., 1998). The E-S route has been used 
by several other workers to prepare granules containing 5-ASA where the focus has 
been on identifying extrusion aids (e.g. Goskonda et al. 1994; Chuong et al., 2008), 
as well as coating methods (Wei et al., 2010) to allow colonic delivery. The 5-ASA 
content of the pellets rarely exceeded 50 wt%. Both Hileman et al. (1993) and 
Rudolph et al. (2001) have reported pellets with high 5-ASA loadings, at 80 and 77.4 
wt% d.b. levels, respectively approaching that desired for a high strength dosage 
form. Higher 5-ASA loadings, approaching the 90% sought in this study, have not 
been achieved, to the authors’ knowledge. 
 
Extrusion-spheronisation 
Extrusion-spheronisation is a multi-stage mechanical process, in which a wet mass is 
forced through a die/screen and afterwards shaped into small spherical/near-spherical 
granules. The liquid phase (generally water) provides interparticle cohesion, 
lubricates particle contacts, promotes wall slip and can also bear some of the stress 
generated during the forming process. However, the pressure exerted on the liquid 
phase during extrusion can cause it to move faster with respect to the particulate 
network, giving rise to variation in the liquid content of the paste within the barrel 
and hence the extrudates. The redistribution of the liquid phase within the solid 
matrix is known as liquid phase migration (LPM) or ‘dewatering’ (Mascia et al., 
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2006). The occurrence of LPM phenomena is affected by the amount and the 
viscosity of the liquid phase, solids packing and structure, along with process 
parameters (e.g. extrusion velocity and die/screen geometry) (Bains et al., 1991). 
 
The physical and chemical properties of the active pharmaceutical ingredient (API) 
are important in paste formulation: the solubility of the API in the liquid phase, its 
particle size characteristics and packing behaviour can affect the amount of liquid 
necessary to obtain a wet mass with the required ‘plasticity’ (Vervaet et al., 1995). 
Hagsten et al. (2008) identified particle size, specific surface area and packing 
behaviour to be key factors affecting the variation in processability (in terms of the 
amount of liquid required for extrusion) of 131 batches of 5-ASA processed by E-S. 
 
Particle size and particle morphology also have a significant influence on the 
rheology of the wet powder masses and the occurrence of LPM. Fielden et al. (1992) 
investigated the influence of lactose size distribution on extrusion behaviour and 
pellet characteristics of lactose/water pastes. Increasing the particle size resulted in 
high extrusion pressures and promoted LPM. Particle packing and solids matrix 
strength are both controlled by particle shape and volume fraction. The porosity and 
pore size distribution in the wet mass, and thereby the permeability of (and 
likelihood of LPM within) the extrudate, are also determined by particle shape and 
volume fraction. The rheological behaviour of suspensions is also sensitive to 
particle shape, with the intrinsic viscosity of particles in the Krieger-Dougherty 
equation known to increase as the shape becomes less spherical (Krieger and 
Dougherty, 1959). 5-ASA crystals are normally needle-like: Kraeger et al. (2004) 
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studied the influence of size and shape of another needle-shaped API, paracetamol, 
on dry powder properties and pelletisation, but the impact of particle shape on 
extrusion-spheronisation has not, to our knowledge, been considered in depth. 
 
E-S aids 
Since the active ingredients do not generally have either lubricant or plasticising 
properties, an extrusion spheronisation aid, namely an excipient able to provide 
mechanical structure and rheological stability, is usually required. Microcrystalline 
cellulose (MCC) is a well established E-S aid whose interaction with water is 
primarily physical rather than chemical. MCC absorbs water and confers the 
appropriate degree of plasticity to the bulk, as well as controlling the movement of 
water through the wet powder mass during extrusion. Fielden et al. (1988) suggested, 
on the basis of thermal studies, that MCC could be described as a ‘molecular 
sponge’: it is capable of physically retaining a large quantity of water within its 
fibrous network, but also of allowing its removal to take place by evaporation and 
when subjected to pressure (e.g. spheronisation).  
 
Not all APIs can be processed with the standard grade of MCC (e.g. Avicel PH101), 
particularly when high loadings (i.e. above 70 wt%) are required. The inability of 
Avicel PH101 either to allow the extrusion (Tomer et al., 2001) or the spheronisation 
(Tomer et al., 2002) of highly-loaded formulations seems to be related to its limited 
water-retention capacity when subjected to pressure. Podczeck and Knight (2006) 
reported that the inability of Avicel PH101 to support E-S of pastes containing        
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80 wt% of a water-insoluble drug (ibuprofen) was associated with the migration of 
water within the formulation during the extrusion stage. 
 
Modified MCC grades, co-processed with varying amounts of sodium 
carboxymethyl cellulose (NaCMC) are able to retain higher quantities of water than 
the standard Avicel PH101 and have therefore been proposed as alternative E-S aids 
for high solids loadings. These modified MCC grades (e.g. Avicel RC591 and 
CL611) were identified by several workers, e.g. O’Connor et al. (1984) and Hileman 
et al. (1993), as promising aids in the extrusion of high solids loading formulations, 
improving extrusion performance and surface quality of the extrudates formed. This 
behaviour was found to be related to their ability to restrict migration of water in the 
wet mass when subjected to pressure (Podczcek et al., 2007). However, the improved 
quality of surface extrudates was always obtained at the expense of rigidity of the 
extrudates, which led to difficulties in spheronisation. In fact, good quality extrudate 
does not always imply its suitability for spheronisation, as demonstrated by Rough 
and Wilson (2005).  
 
The aim of the current work was to assess the feasibility of an E-S route for the 
manufacture of pellets with high 5-ASA loading (i.e. > 80 wt%). Initial attempts to 
produce pellets in a radial screen extruder (Nica System, model E140), using Avicel 
PH101 as the E-S aid and water as the liquid binder, were undertaken. A screening 
design of experiments, aiming to identify the most critical process and formulation 
parameters for the obtainment of pellets with desirable properties (e.g. high drug 
content, low friability, high density and sphericity), was determined. However, 
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variability in extrudate water content coupled with a lack of reproducibility of pellet 
properties was generally observed, in such a way that the experimental design was 
invalidated. In particular, the optimal amount of water necessary to achieve both a 
plastic mass suitable for extrusion, and extrudates with appropriate characteristics for 
spheronisation, could not be identified. A likely hypothesis to explain the variability 
in extrudate water content could be that pastes undergo dewatering when subjected to 
high pressures, i.e. during the extrusion process. A systematic study was therefore 
performed in a ram extruder apparatus to investigate the influence of both solid phase 
components, namely the active ingredient (physical and chemical characteristics) and 
the E-S aid, on the rheological properties of highly-loaded 5-ASA pastes undergoing 
extrusion. 
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2. MATERIALS AD METHODS 
2.1 Materials 
5-aminosalicylic acid (5-ASA, mesalamine) (Erregierre S.p.A., Bergamo, Italy) was 
used both as received from the supplier (un-milled, labelled uM) and after 
micronisation. Calcium sulphate dihydrate (CaSO4·2H2O, labelled CaSO4) (Fisher 
Scientific Inc., Pittsburgh, PA, USA) and a high density grade of 5-ASA (labelled   
5-ASA HD) (Farchemia S.p.A, Treviglio, Italy) were chosen as reference materials 
to investigate the influence of prolate (needle-like) particles on the extrusion process. 
The standard Avicel PH101 grade of microcrystalline cellulose (MCC) (IMCD 
S.p.A, San Donato Milanese, Italy) was used as the primary extrusion-spheronisation 
aid. Two modified grades of MCC co-processed with sodium carboxymethyl 
cellulose (NaCMC), namely Avicel RC591 (12 wt% NaCMC) and Avicel CL611  
(15 wt% NaCMC), were evaluated as alternatives to Avicel PH101. Reverse osmosis 
water was used as the binder for paste preparation. 
 
2.2 Methods 
2.2.1 Micronisation 
Two batches of micronised 5-ASA were obtained by milling uM in different 
equipment. The BM batch was prepared in a planetary ball mill (Pulverisette 7, 
Fritsch, Germany); the grinding process was performed in a 45 mL stainless steel 
grinding bowl containing fourteen stainless steel balls (20 mm diameter), for 12 h at 
250 rpm. A standard Teflon seal was positioned between the lid of the grinding bowl 
and the bowl itself. The powder-to-ball weight ratio was 1/35. The JM batch was 
kindly provided by IMS Micronizzazioni S.p.A (Milano, Italy). The batch was 
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produced by air-jet milling (Chrispro® Jet-Mill, Micro-Macinazione S.A., Molinazzo 
di Monteggio, Switzerland). The mill had a spiral chamber of 300 mm diameter. The 
milling gas was air, injected through 8 nozzles at 8 bar. The starting material was 
charged (700-750 g min-1) through a venturi feeder, using a pressure of 8 bar. 
 
2.2.2 Powder characterisation 
 2.2.2.1 Powder X-Ray Diffraction 
Powder X-ray diffraction (PXRD) was performed on a Philips PW1050/25 
diffractometer (Philips Analytical Inc., Natick, MA, USA) using Cu-Kα radiation    
(λ = 1.54 Å) generated with 30 kV and 15 mA. Samples were packed in the same 
aluminum sample holder to promote reproducibility of conditions, taking care also to 
minimize preferred orientation effects. The operating conditions were as follows: 
scan speed 0.5° 2θ min-1; step size 0.02° 2θ; range  5 ≤ 2θ ≤35°. 
 
2.2.2.2 Thermal analysis  
Differential scanning calorimetry (DSC) was performed on a DSC2010 calorimeter 
(TA Instruments, New Castle, DE, USA), between ambient and 350 °C, under 
nitrogen purging at 70 mL min-1. DSC runs were performed on 2-3 mg samples in 
non-hermetically sealed aluminum pans at a scanning rate of 10 K min-1. Data 
reported are the average of at least 3 determinations. 
 
2.2.2.3 Solid, bulk and tapped densities 
The solid density of the three batches of 5-ASA (uM, JM and BM) was evaluated 
using a Micromeritics AccuPyc 1330 helium pycnometer (Norcross, GA, USA). The 
gas pressure was set to be 0.087 psia with a purging time of ~ 15  min. Samples of 
0.3-0.5 g were analysed in a controlled environment (26.1 °C, relative humidity 
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50%). All the analyses were conducted in triplicate. For the bulk and tapped 
densities, a sample mass of about 50 g was poured into a 250 mL glass cylinder 
mounted on an automated tap density tester (Stampfvolumeter STAV 2003, 
Engelsmann A.G., Ludwigshafen, Germany). The volume of powder was determined 
after zero and 1,250 taps, and the bulk and tapped densities were calculated as the 
ratio of the mass to the corresponding volumes, respectively. The results presented 
are the mean of three replicates. 
 
 2.2.2.4 BET surface measurements 
Surface area determination was performed by means of a SA3100 Surface Area 
Analyzer (Beckman Coulter, UK) according to the BET method using N2 as 
adsorbate gas (USP 32 Physical Test. Specific Surface Area. Volumetric Method). 
Prior to surface area measurements, the samples (approximately 2 g) were degassed 
at 90 °C under vacuum (0.4 Pa) for 1 h to remove physically adsorbed gases (water 
vapour). The measurement was carried out in triplicate. 
 
2.2.2.5 Particle size and shape 
Particle size characterisation was performed using a laser light scattering and an 
automated particle imaging apparatus. The laser scattering device was a Coulter LS 
230 (Beckman Coulter Inc., Fullerton, CA, USA) equipped with variable speed, 
microvolume and dry powder modules. Lorentz-Mie theory (diffraction-diffusion) 
was used as the optical model. The refractive indices of 5-ASA and CaSO4 were 
1.691 and 1.521, respectively. Isopropyl alcohol (refractive index 1.377) and pure 
sunflower oil (refractive index 1.473) were used as suspending agents for 5-ASA and 
CaSO4, respectively. Powder samples were sonicated prior to analysis to break up 
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potential aggregates. Data collected are reported in terms of volume-based relative 
size distribution. 
 
The particle imaging device (Morphologi® G3, Malvern Instruments Ltd, 
Worcestershire, UK) was able to determine both particle size and shape. The 
machine featured a Nikon CFI 60 Brightfield/Darkfield optical system and a 1/1.8” 
global shutter progressive scan CCD camera (5 megapixels). Powder samples          
(3 µm3) were dispersed using the integrated sample dispersion unit, via an 
instantaneous pulse of compressed air (range: 0.8-2.5 bar depending on the particle 
size of the powders). Image analyses were performed at 20× and 50× magnification, 
according to a standard operating procedure. Particle dimensions were quantified in 
terms of volume-based size distributions. Particle shape was quantified in terms of 
circularity (calculated as 4πA/p2, where A is the projected area and p the projected 
perimeter of the particle) and aspect ratio (defined as minor axis/major axis). At least 
60,000 particles were analysed. Two-dimensional micrographs were also collected. 
 
2.2.3 Paste preparation 
Dry powders (200-300 g) were placed in a planetary mixer (Kenwood KM 200, 
Southampton, UK) and different amounts of liquid binder slowly poured onto the 
powder surface. Granulation was performed at a constant speed of 25 rpm for         
10 min. The process was occasionally interrupted to scrape off the material adhering 
to the wall of the bowl and the mixing blade. Mixtures of 5-ASA batches and MCC 
were dry blended for 5 min prior to liquid addition. Pastes were stored for 24 h in 
airtight containers prior to extrusion to allow the water to equilibrate throughout the 
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mixture. All experiments were performed at room temperature in an air-conditioned 
laboratory (21 ± 3 °C, humidity 35 ± 5%). 
 
2.2.4 Centrifuge testing 
The centrifuge used was an MSE minor ‘s’ (Meadowrose Scientific Ltd, Oxfordshire, 
UK) operating over the range of 500–4600 rpm. Paste samples were filled into 
cylindrical copper containers (22 mm internal diameter (i.d.), 85 mm height), 
featuring a punctured base (several holes, i.d. 2 mm), to a sample height of 50 mm.  
A filter paper (1 µm pore size) was placed at the bottom of the container to prevent 
loss of solid through the holes during centrifugation. The container was located in a 
stainless steel holder attached at the end of a shaft rotating around the centrifuge axis. 
Samples were weighed before and after centrifugation performed at constant 
rotational speed for 60 and 120 min; trials were performed at different rotational 
speeds. All the experiments were carried out at room temperature (21 ± 1 °C) and 
environmental relative humidity (45 ± 5%) to reduce the effects of water 
evaporation. 
 
The centrifugal pressure, Pc, was calculated by the following relationship (Hassler 
and Brunner, 1945): 
 
  
Pc = 0.5ρω
2 rout
2 − rin
2( )    (1) 
 
where ρ is the liquid phase density, ω the angular velocity, and rin (75 mm) and rout 
(85 mm) are the radial distances from the centrifuge axis to the inner and outer faces 
of the sample, respectively. Final water content (and drainage) was quantified in 
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terms of the water/ MCC mass ratio, calculated as the mass of liquid retained by the 
sample after being centrifuged and the amount of MCC present in the sample. 
 
2.2.5 Extrusion-spheronisation 
Extrusion testing was performed in a computer-controlled ram extruder 
(Zwick/Roell, Zwick Testing Machines Limited, Leominster, UK). The apparatus 
consisted of a 25 mm i.d. barrel, a ram attached to the cross-head of the strain frame 
and a load cell that measured the applied force and the ram displacement, as 
described by Rough et al. (2000). Various concentric cylindrical square-entry dies 
with different die land lengths (L) and diameters (D) were used. All surfaces in 
contact with the paste were stainless steel except the piston, which featured a Teflon 
seal. The barrel was filled with approximately 80 g of paste; to ensure uniform 
compaction a pre-load (range: 1-2 kN) was applied. Pastes were extruded at a 
constant ram velocity (Vram) in the 0.1-10 mm s
-1 range. Extrudates were spheronised 
in a 120 mm diameter cross-hatch plate spheroniser (Caleva, Sturminster Newton, 
Dorset, UK), at a constant speed of 1,600 rpm. Pellets were dried in a vacuum oven 
at 40 °C for 24 hours. 
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3. RESULTS AD DISCUSSIO 
3.1 Ram extrusion study of Avicel PH101-based 5-ASA pastes  
Extrusion pressure (Pex)-ram displacement profiles for Avicel PH101-based pastes 
containing increasing amounts of uM were compared at different experimental 
conditions (die length and diameter, ram velocity and paste water content). A steady 
increase in Pex during the extrusion was generally observed for all the formulations 
tested. The phenomenon was more evident at lower extrusion velocities (data not 
shown). LPM is often manifested as a divergence from the expected steady-state Pex 
value, and it was most noticeable with single-holed capillary dies having a high L/D 
ratio and/or at relatively low ram (and hence extrusion) velocities. The effect of die 
geometry and extrusion velocity on LPM has been discussed elsewhere (e.g. Rough 
et al., 2002). In order to mitigate the effects of LPM caused by relatively low ram 
velocities, a square-entry multi-holed die (6 notionally identical holes, D = 1 mm, L 
= 4 mm, evenly spaced in a ring, radial distance from the die centre 7.5 mm) was 
employed for the majority of the tests, so that relatively low extrusion velocities 
could be attained with correspondingly high ram velocities (the ram velocity being 
directly proportional to the number of die holes multiplied by the extrusion velocity).  
 
The paste water content was chosen to be just sufficient to give a plastic mass and 
suitable paste rheological properties for extrusion. The water/Avicel PH101 ratio was 
varied systematically to evaluate the influence of moisture content on the E-S 
process. The 1.2:1 water/Avicel PH101 ratio (by mass) was identified, by 
centrifugation testing (see section 3.4.1), as the lower liquid limit for a plastic mass. 
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An increase in the liquid content resulted in over-wet pastes, whereas a decrease 
yielded dry and stiff pastes that were unsuitable for extrusion. 
 
Figure 1.1: Extrusion profiles for Avicel PH101-based pastes containing (A) 10, (B) 20, (C) 30 and 
(D) 50 wt% uM at Vram= 1 mm s
-1, 6-holed die (D = 1 mm, L = 4 mm). Water:Avicel PH101 ratio = 
1.2:1. Inset shows a magnification of profile B, indicating how LPM occurred even at low drug 
loadings. 
 
By way of example, Figure 1.1 shows the Pex-ram displacement profiles of pastes 
containing uM at 10-50 wt% of the total solids, performed using the multi-holed die 
at a ram velocity of 1 mm s-1 (corresponding to an extrusion velocity of 104 mm s-1). 
For a given ram displacement, Pex increases as the uM content increases, indicating 
that LPM was related to the uM loading in the paste. For comparison, extrusion of a 
water/Avicel only paste under these conditions gave a steady Pex value of ~ 2 MPa. 
Above 50 wt% 5-ASA, substantial dewatering of the paste was observed, resulting in 
Pex approaching the mechanical limit of the apparatus. A systematic study of 5-ASA 
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loading with Avicel PH101 was therefore not possible as LPM effects dominated the 
extrusion behaviour. 
The increase in LPM with 5-ASA loading could arise from either a physical or a 
chemical interaction of the API with Avicel PH101, thereby modifying the 
rheological properties of the final wet mass. 5-ASA is sparingly soluble in water and 
therefore is present as ‘hard’ solids within a ‘soft’ MCC matrix. At high drug 
loadings, 5-ASA could affect the ability of the Avicel PH101 to support extrusion. 
Alternately, as 5-ASA solution is acidic, the liquid holding capacity of the MCC 
could be modified. 
 
The effect of the physical properties of 5-ASA, specifically the particle size and 
shape, and the potential influence of 5-ASA acidity on the behaviour of Avicel 
PH101-based pastes during extrusion were therefore investigated. In addition, the 
performance of two colloidal grades of MCC, namely Avicel RC591 and CL611, as 
E-S aids was compared to that of the standard Avicel PH101. 
 
3.2 Influence of 5-ASA acidity 
5-ASA is a zwitterionic drug, with pKa values of 6.0, 3.0 and 13.9 corresponding to 
the NH3+, COOH and OH groups, respectively (Allgayer et al., 1985). Since water 
was used as the liquid binder, 5-ASA could alter the pH of the mobile phase, thereby 
influencing the ability of  the MCC to work as a molecular sponge. The liquid 
retention ability of Avicel PH101-based pastes was therefore assessed using RO 
water and saturated aqueous solutions of 5-ASA (pH = 4 ± 0.05, ~ 0.9 g L-1) as the 
wetting/binding agent. Data were collected from centrifuge and ram extrusion 
testing, performed on different pastes prepared with 45-65 wt% liquid phase. The 
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results from these tests did not show any significant differences between water and  
5-ASA saturated solution as binder, thereby indicating negligible influence of 5-ASA 
acidity on MCC liquid retention and flow behaviour. 
 
3.3 Influence of 5-ASA physical properties 
In order to assess the effect of 5-ASA physical properties on the extrusion behaviour 
of Avicel PH101-based pastes, three batches of 5-ASA, having different particle size 
and shape characteristics and hence different bulk properties, were investigated. The 
5-ASA batches were:  
(i) the material as received by the supplier, labelled uM;  
(ii) the material in (i) after being subjected to jet milling, labelled JM; 
(iii) the material in (i) after being subjected to ball milling, labelled BM.  
Their particle size characteristics, measured by the laser scattering and automated 
microscope devices, are summarised in Table 1.1. 
 
Table 1.1: Particle size data for 5-ASA batches.  
 
 
Both milling procedures reduced the particle dimensions, as indicated by the d10, d50 
and d90 values. Divergences between the two measuring techniques are evident: the 
laser scattering data indicate that the BM material has a smaller particle size and 
narrower size distribution than JM whereas the opposite trend is indicated by the 
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microscopy results. These differences were not surprising, as the devices employ 
different techniques and needle-like particle shapes further complicate the analysis. 
The micrographs in Figure 2.1 confirm the difference in size and shape between the 
different batches. The BM particles are smaller than those in the other batches, while 
the JM particles are still needle-like although with a smaller aspect ratio than uM. 
 
Figure 2.1: Micrographs of (a) uM, (b) JM and (c) BM batches of 5-ASA (magnification 50×). 
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The reliability of laser scattering for aspherical particles has been discussed by 
Latimer et al. (1978). In contrast, the microscope system captures 2-dimensional 
images of the particles and calculates particle size and shape parameters from these. 
Aggregates of BM particles are evident in Figure 2.1(c), which are likely due to 
uneven dispersion of the sample in the microscopy preparation step: these aggregates 
will skew the particle size analysis data away from the trends indicated by the 
micrographs and laser sizing results. The need for careful sample preparation is 
evident. 
 
Figure 3.1: Shape parameters for uM, JM and BM batches of 5-ASA obtained from image analysis: 
(a) circularity and (b) aspect ratio. 
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The particle shape distribution data in Figure 3.1 quantify the differences evident in 
the 2-D micrographs in Figure 2.1. Other measures of shape could be readily 
calculated from the data sets: we chose to report circularity and aspect ratio as these 
capture the key results of milling. Ball milling increases the circularity of the 5-ASA 
from the broad distribution centred at 0.45 obtained for both uM and JM materials to 
a narrower distribution with a mean of 0.85. The aspect ratio distributions in Figure 
3.1(b) reflect the above differences between uM and BM. Figure 3.1(a) also indicates 
that jet milling gives a noticeably broader distribution in circularity. 
 
Table 2.1: Density values (± s.d.) and specific surface area for 5-ASA batches. 
 
 
Milling therefore changed the particle dimensions and shape. The impact on the 
powder handling properties is summarised in Table 2.1. The solid density values are 
very similar, as expected. In comparison with the uM values, the data indicate that 
the jet milling process did not modify either the bulk or the tapped densities of the   
5-ASA powder considerably. The tapped density decreases slightly after jet milling, 
probably due to electrostatic attractive forces becoming stronger as the particle 
dimensions decrease, increasing particle aggregation and thereby leading to poorer 
packing ability. In contrast, the bulk and tapped density values for BM are about 
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50% and 60% higher, respectively, than the uM values. The differences in packing 
between JM and BM are consistent with the change in particle morphology and 
dimensions. The specific surface area (BET) results confirm the reduction in particle 
size upon milling. The trend supports the laser scattering sizing results (Table 1.1) in 
that the BM surface area is greater than that of the JM. 
 
Figure 4.1: X-ray diffraction patterns for uM, JM and BM batches of 5-ASA. Profile baselines are 
shifted for clarity. 
 
Modification of the solid state on milling was evaluated by PXRD and DSC. Figure 
4.1 shows similar PXRD patterns for the three materials. The peak angular positions 
are in excellent agreement, indicating that milling did not affect the crystalline form 
of 5-ASA. Small differences in the peak relative intensities are attributed to preferred 
orientation effects; this is consistent with the differing morphology of the 5-ASA 
crystals, being predominantly prolate for the uM and the JM batches, and more 
pseudo-spherical for BM, as discussed above. Similarly, thermograms of all samples 
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showed a single endothermic melting event at approximately 280 °C with a 
comparable associated enthalpy (about 980 J g-1). 
 
3.3.1 Ram extrusion study 
The effect of 5-ASA particle size and morphology on Avicel PH101 based pastes 
undergoing extrusion was investigated at varying experimental conditions of die 
length and diameter. Figure 5.1 presents some of the extrusion pressure-ram 
displacement profiles obtained for (a) 50 and (b) 90 wt% loaded 5-ASA pastes, 
performed at Vram = 1 mm s
-1 using a 6-holed square-entry die (D = 1 mm, L = 4 mm). 
 
Figure 5.1: Extrusion profiles for Avicel PH101/5-ASA (uM, BM and JM) pastes at Vram= 1 mm s
-1, 
6-holed die (D = 1 mm, L = 4 mm). 5-ASA loading: (a) 50 and (b) 90 wt%. Points labelled OJM and 
OBM in (b) represent onset of flow for JM and BM pastes, respectively. 
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Figure 5.1(a) compares the ram extrusion profiles for 50 wt% loaded 5-ASA pastes. 
The 50 wt% loaded uM paste starts extruding at an initial Pex value of ~ 2 MPa, but 
soon after the onset of the extrusion Pex steadily increases, reaching a final value of 
~41 MPa. This phenomenon is consistent with significant dewatering occurring 
during extrusion, leading to an over-wet initial mass, requiring a smaller stress to 
start flowing. Subsequent portions of paste being extruded are consequently drier, 
and higher pressures are hence required to maintain flow. As discussed in section 
3.1, LPM increases with increasing drug loading; at 90 wt% loading, the uM paste 
was unable to be extruded since severe dewatering occurred, yielding a dry 
immovable plug in the barrel. 
 
50 wt% loaded JM and BM pastes start extruding at slightly higher Pex values than 
uM, namely 13 and 4 MPa, respectively; however, unlike uM, the extrusion pressure 
reaches a steady state instead of progressively increasing, indicating that dewatering 
is minimal. Hence, a decrease in 5-ASA particle size improves the flow 
characteristics of wet powder masses and allows LPM to be considerably reduced or 
eliminated. This is particularly important when the longest particle dimension 
approaches the size of the die diameter.  However, differences between JM and BM 
data are observed; the extrusion profiles for BM pastes are smooth and continuous, 
unlike JM which shows more fluctuation. The more jagged appearance of the Pex 
profiles for the JM paste could be due to the greater tendency of the material to stick-
slip at the die wall. The differences between JM and BM are more pronounced when 
higher drug loadings (90 wt%, Figure 5.1(b)) are processed. The extrusion profile for 
the JM paste shows a compaction stage prior to the extrusion of the wet mass, most 
likely due to the different packing properties of the milled materials. The initial 
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extrusion pressure of 90 wt% JM paste (7 MPa) is almost half that of the 
corresponding 50 wt% loaded formulation (13 MPa), despite the increase in drug 
loading; this is once again consistent with liquid phase migration occurring during 
the extrusion, as is also evident from the steady increase in Pex up to the final value 
of 33 MPa. In contrast, the BM paste shows a relatively steady flow state throughout 
the extrusion, after an initial extrusion pressure of ~ 6 MPa. 
 
These results indicate that the particle size and shape of 5-ASA are critical 
parameters affecting the packing as well as the flow properties of the pastes. On the 
basis of the different behaviour of JM and BM pastes, we postulate that the shape of 
the 5-ASA particles, in addition to their size, is a key factor in the extrusion of 
highly-loaded pastes with Avicel PH101 as an extrusion aid at this length scale. In 
order to confirm this hypothesis, the behaviour of a reference material, having a 
similar particle morphology to that of 5-ASA, undergoing extrusion was 
investigated. 
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3.3.2 Influence of needle-like morphology of 5-ASA: control test 
The dehydrate (gypsum) polymorph of calcium sulphate (labelled CaSO4) was 
selected as a reference material: it is a sparingly soluble material with prolate shaped 
particles similar to those of 5-ASA. In order to assess the influence of particle shape 
of the active ingredient on Avicel PH101-based pastes undergoing extrusion, a 
commercial high density grade of 5-ASA (labelled HD) was also investigated. 
Particle size/shape characteristics and micrographs of CaSO4 and HD are reported in 
Table 3.1 and Figure 6.1, respectively. Divergences between the laser scattering and 
the automated microscope as sizing methods were again evident. HD and CaSO4 
particles are prolate, even though their aspect ratios are different from that of uM 
crystals (Figure 3.1). The uM particles are more tapered whereas HD and CaSO4 
crystals are more coarse. Moreover, HD particles are slightly more acicular than 
CaSO4 ones, as confirmed by the circularity data in Table 3.1. 
 
Table 3.1: Particle size and shape values for CaSO4 and 5-ASA HD. 
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Figure 6.1: Micrographs of (a) CaSO4 and (b) 5-ASA HD (magnification 50×). 
 
A ram extrusion study, at varying conditions of die length and diameter and 
extrusion velocity, was performed on Avicel PH101-based pastes containing 
increasing amounts of active ingredient. Since CaSO4 and 5-ASA differ in terms of 
their solid density values (2.32 and 1.53 g cm-3, respectively), pastes were prepared 
on a volume rather than a weight basis. No sedimentation or segregation effects were 
observed. 
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Figure 7.1: Extrusion profiles for Avicel PH101-based pastes containing 60 vol% of uM, 5-ASA HD 
or CaSO4 at Vram = 1 mm s
-1, 6-holed die (D = 1 mm, L = 4 mm). 
 
Figure 7.1 presents the extrusion pressure-ram displacement profiles for 60 vol% 
active ingredient/Avicel PH101 pastes. In agreement with the particle shape 
characteristics, the HD and CaSO4 pastes show a similar trend in the extrusion 
profile to that observed for uM, namely a steady increase in Pex with ram 
displacement, indicating that dewatering of pastes is occurring during extrusion. 
Interestingly, LPM is more pronounced when the HD and CaSO4 pastes are extruded, 
thus suggesting that particle shape, rather than particle size, is the critical parameter 
in the extrusion of Avicel PH101-based pastes. Both CaSO4 and HD pastes yielded 
over-wet surface extrudates which could not be spheronised. 
 
 
Extrusion-spheronisation of highly-loaded 5-ASA multiparticulate dosage forms  CHAPTER 1 
__________________________________________________________________________________ 
 53 
3.4 Influence of alternative MCC grades as E-S aids 
The previous section demonstrated the influence of API shape on the extrusion of 
Avicel PH101/‘hard API’ pastes. The potential influence of the E-S aid was also 
investigated. The water retention ability, rheology and the performance as an E-S aid 
of Avicel PH101 for high 5-ASA loadings is now compared to that of two colloidal 
MCC grades containing NaCMC, namely Avicel RC591 and CL611. 
 
3.4.1 Centrifuge testing 
The water retention ability of the standard MCC and the colloidal grades was 
assessed by centrifugation, performed on pastes containing different amounts of 
water. Plots of water/MCC mass ratio vs centrifugal pressure are presented in Figure 
8.1.  
 
Figure 8.1: Water/MCC mass ratio vs centrifugal pressure profiles for Avicel (a) PH101, (b) RC591 
and (c) CL611; (d) water loss profiles of MCC pastes at 180 kPa centrifugal pressure. 
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Figure 8.1(a) shows that Avicel PH101 is able to retain an amount of water almost 
equal to its own mass, even after the application of high centrifugal forces. However, 
for water contents above 50 wt%, the water-holding ability of Avicel PH101 steadily 
decreases with increasing centrifugal pressure. After being subjected to the highest 
centrifugal pressure value (180 kPa) for 60 min, all PH101 pastes reached a minimal 
water/MCC value of about 0.8. This suggests that the water/Avicel PH101 ratio of 
1:1.2 might represent the maximum water quantity that the microcrystalline fibrils 
are able to retain within their internal structure. Once this saturation level is reached, 
additional water would be loosely associated in the free space between the cellulose 
particles and therefore readily lost during centrifugation. Extended centrifuge testing 
over 120 min (data not shown) gave similar results to those performed at 60 min. 
Figures 8.1(b) and (c) show that both the colloidal MCC grades are able to retain 
more than twice their own mass of water even when subjected to the highest 
centrifugal pressures. A plot of percentage water loss against initial paste water 
content for the three MCC grades (Figure 8.1(d)), at 180 kPa centrifugal pressure, 
also gives an indication of the water-retaining ability of the pastes. In order to 
validate the efficiency of the centrifuge testing, a control study using inert glass 
spheres (ballotini) having a particle size similar to that of MCC was performed (data 
not shown). As expected, the water added to the ballotini ‘paste’ was completely 
drained after the centrifuge run. The greater water-retaining ability of the colloidal 
MCC grades was further confirmed by ram extrusion testing. 
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3.4.2 Ram extrusion studies 
 3.4.2.1 MCC pastes 
The rheological behaviour and the water retention ability of the standard PH101 
grade of MCC was compared to that of the modified RC591 and CL611 grades. Ram 
extrusion testing was performed using a square-entry single-holed capillary die (D = 
2 mm, L = 2 mm) over a ram displacement of 100 mm, on 50, 55, 60 and 65 wt% 
water/MCC pastes, at Vram speeds of 0.1, 1 and 10 mm s
-1. 
 
Table 4.1: Average Pex values for MCC/water pastes at Vram= 0.1, 1 and 10 mm s
-1, single-holed 
capillary die (D = 2 mm, L = 2 mm). Asterisked values indicate LPM: initial and final extrusion 
pressures are reported for a ram displacement of 100 mm. Coefficient of variation (CV, in %) given in 
brackets. 
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Table 4.1 lists the average Pex values for the formulations tested. For those 
formulations which exhibited LPM, initial and final Pex values, marked by an 
asterisk, are reported. As expected, for a given MCC grade, the extrusion pressure 
increases with increasing Vram, and decreases with increasing water content. 
All PH101 pastes exhibited liquid phase migration at the lowest (0.1 mm s-1) and 
intermediate (1 mm s-1) ram velocities, whereas at the highest Vram (10 mm s
-1) LPM 
was observed only for the 65 wt% water/PH101 formulation. Avicel RC591 only 
showed some LPM at Vram= 0.1 mm s
-1, while the intensity of dewatering for RC591 
pastes (profiles not shown) was always less pronounced than that observed for the 
corresponding PH101 pastes. LPM was not observed with Avicel CL611, and 
smooth extrusion profiles were obtained at all combinations of Vram and water 
content investigated. By way of example, Figure 9.1 presents Pex profiles for 50 wt% 
water/MCC pastes performed at Vram = 1 mm s
-1.  
 
Figure 9.1: Extrusion profiles for 50 wt% water/MCC (Avicel PH101, RC591 and CL611) pastes at 
Vram = 1 mm s
-1, single-holed capillary die (D = 2 mm, L = 2 mm). 
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The ram extrusion study, in agreement with the centrifuge results, demonstrates the 
improved ability of colloidal MCC grades to hinder water migration when subjected 
to pressure. 
 
 3.4.2.2 Colloidal MCC/5-ASA pastes 
RC591 and CL611 grades of MCC were investigated as alternative E-S aids to 
Avicel PH101 in 5-ASA based pastes. The amount of water used for paste 
preparation was selected on the basis of the centrifuge testing. Since colloidal MCC 
grades have a greater water-retaining ability than the standard PH101, the amount of 
water necessary to obtain a plastic mass suitable for extrusion was greater. The 
water/colloidal MCC mass ratio selected was 1.5:1; both a wet mass and extrudates 
with appropriate characteristics of plasticity could be obtained with this amount of 
water. 
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Figure 10.1: (a) Extrusion profiles for 50 wt% uM/MCC (Avicel PH101, RC591 and CL611) pastes 
at Vram = 1 mm s
-1, 6-holed die (D = 1 mm, L = 4 mm) and (b) water content profile of extrudates 
throughout ram extrusion and the remaining paste billet. Horizontal lines in (b) indicate initial paste 
water content of colloidal MCCs (grey) and Avicel PH101 (black). Error bars indicate standard error 
(3 replicates). 
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Figure 10.1(a) shows an example of the Pex-ram displacement profiles obtained for 
50 wt% uM/MCC pastes. By replacing the standard MCC grade with the colloidal 
ones, LPM was reduced or eliminated. In contrast to the Avicel PH101 based paste, 
Pex for the colloidal grades of MCC reached steady state shortly after extrusion 
started, indicating that little dewatering occurred. This was confirmed by monitoring 
the water content distribution of both the extrudate during ram extrusion and the 
remaining billet within the barrel (see Figure 10.1(b)). The Avicel PH101 based 
formulation showed a relatively large difference in extrudate water content from that 
of the initial paste. This is manifested as an over-wet extrudate and a relatively dry 
paste billet in the barrel. On the contrary, the water content of the extrudate and the 
billet for both the colloidal MCC grades is close to the initial value, thereby 
indicating that the water was strongly held within the MCC-NaCMC fibril network.  
 
The extrudates obtained were subjected to spheronisation: both RC591 and CL611 
based formulations yielded spherical granules, whereas PH101 failed, yielding over-
wet extrudates that aggregated during spheronisation. 
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Figure 11.1: Extrusion profiles for MCC-based pastes containing 90 wt% of (a) uM, (b) JM and (c) 
BM at Vram = 1 mm s
-1, 6-holed die (D = 1 mm, L = 4 mm). Points labelled ORC591, OCL611 and OPH101 
in (a) and (c) indicate the onset of extrusion for Avicel RC591, CL611 and PH101 pastes, 
respectively. 
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The behaviour of these colloidal MCC grades with high loadings of 5-ASA           
(i.e. 90 wt%) was also assessed. Figure 11.1 presents the extrusion profiles obtained 
for 90 wt% API loaded pastes with uM, JM and BM. Both the colloidal MCC grades 
allowed a 90 wt% uM loaded formulation to be extruded (Figure 11.1(a)), whereas 
Avicel PH101 failed (see section 3.3.1). However, both uM/RC591 and uM/CL611 
started extruding at relatively high values of Pex (41 and 28 MPa, respectively), after 
an extended compaction stage coupled with severe liquid phase migration throughout 
the extrusion. Analogously, JM pastes (Figure 11.1(b)) showed a similar extrusion 
trend, even though the overall Pex values are slightly lower. Conversely, BM-based 
pastes (Figure 11.1(c)) gave steady extrusion profiles, following the onset of 
extrusion (occurring at 10 MPa for the CL611-based paste and at ~ 11 MPa for the 
PH101 and RC591 ones). The importance of particle shape, rather than particle size 
of 5-ASA in the extrusion process of MCC based pastes, is once again confirmed. 
 
Previous workers, e.g. Harrison et al. (1985), demonstrated that steady-state flow 
during the extrusion process is necessary to obtain good quality extrudates (i.e. ones 
with a smooth surface); this was confirmed in the current study. However, good 
quality extrudate does not always imply its suitability for spheronisation. In fact 
BM/PH101 pastes yielded good quality (without surface defects) extrudates, but 
these were not able to give satisfactory spheres when subjected to spheronisation; the 
extrudates obtained did not have sufficient plasticity either to break up or to be 
rounded off within the spheroniser (Figure 12.1(a)). However, increasing the 
moisture content in the paste formulation, to enhance plasticity, led to over wet-
surface extrudates and resulted in uncontrollable agglomeration. Conversely, both 
BM/RC591 and BM/CL611 pastes exhibited steady extrusion profiles and 
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furthermore yielded extrudates that were able to be broken up in the spheroniser and 
to form satisfactory spheres (Figure 12.1(b)).  
 
Figure 12.1: Micrographs of dried pellets containing 90 wt% BM and 10 wt% (a) Avicel PH101 and 
(b) CL611. Extrusion: 6-holed die (D = 1 mm, L = 4 mm); Vram = 1 mm s
-1. Spheronisation: 10 min; 
1600 rpm. 
 
The overall results indicate that particle size and shape of the API (and thereby an 
appropriate process of milling) are important parameters to be taken into account 
when high drug loadings need to be processed by extrusion-spheronisation. 
Analogously, the E-S aid type used is also an important issue to be considered, as it 
can determine the feasibility of the spheronisation process and/or the characteristics 
of the final product. The influence of process parameters (e.g. spheronisation time 
and speed) on the properties of the final pellets will be investigated further. 
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4. COCLUSIOS 
 
The feasibility of an E-S route for the manufacture of highly-loaded 5-ASA 
multiparticulate dosage forms was assessed. The influence of the API chemical and 
physical properties on the rheological behaviour of MCC-based pastes undergoing 
extrusion was investigated. Two batches of micronised 5-ASA, with different 
particle size and shape characteristics, were prepared and their extrusion behaviour 
was compared to that of the starting material. The performance as E-S aids of the 
standard Avicel PH101 grade of MCC and of colloidal ones (i.e. Avicel RC591 and 
CL611), alongside high loadings of 5-ASA, was also evaluated. Centrifugation 
testing, supported by ram extrusion studies, was used to establish the water retention 
ability of paste materials and to determine the minimal water content required to 
obtain a wet mass with an appropriate degree of plasticity for extrusion and 
spheronisation. 
 
Acute liquid phase migration (LPM), resulting in a non-uniform distribution of water 
within the extrudates, was generally observed for the 5-ASA/Avicel PH101 paste 
formulations. This was demonstrated to be dependent on both the drug load and the 
type of extrusion aid. Drug particle morphology (needle-like) was identified as the 
critical parameter, which was confirmed by extruding calcium sulphate/MCC pastes, 
where the sulphate polymorph was selected to match the 5-ASA shape. A reduction 
in particle size, combined with a change in particle morphology, allowed LPM to be 
considerably reduced or eliminated. The effect of pH on MCC behaviour was found 
to be negligible. Colloidal grades of MCC were identified to be promising 
alternatives to the standard PH101 in extrusion of high 5-ASA loadings, due to their 
ability to hinder water migration when subjected to pressure. Based on the results 
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obtained, a multiparticulate E-S formulation containing not less than 90 wt% 5-ASA 
could be developed by combining an accordingly micronised API and colloidal MCC 
grade. 
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omenclature 
A  projected area of particle (m2) 
d10, d50, d90 particle size (m) 
D  die land diameter (m) 
L  die land length (m) 
p  projected perimeter of particle (m) 
Pc  centrifugal pressure (Pa) 
Pex  extrusion pressure (Pa) 
rin, rout  radial distances (m) 
t  time (s) 
Vram  ram velocity (m s
−1) 
 
ρ  liquid phase density (kg m−3) 
ω  angular velocity (rad s−1) 
Abbreviations 
5-ASA  5-aminosalicylic acid 
API  active pharmaceutical ingredient 
B.E.T  Brunauer-Emmett-Teller  
BM  ball-milled 5-ASA 
CaSO4  calcium sulphate dihydrate 
CD  Crohn’s disease 
DSC  differential scanning calorimetry 
E-S  extrusion-spheronisation 
HD  high density grade of 5-ASA 
JM  jet-milled 5-ASA 
LPM  liquid phase migration 
MCC  microcrystalline cellulose 
NaCMC sodium carboxymethyl cellulose 
PXRD  powder X-ray diffraction 
UC  ulcerative colitis 
uM  un-milled 5-ASA 
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A FACTORIAL APPROACH TO HIGHLY-LOADED 5-ASA 
PELLETS BY EXTRUSIO-SPHEROISATIO 
 
G. Di Pretoro, L. Zema, L. Palugan, D.I. Wilson, S.L. Rough, A. Gazzaniga. A factorial approach to 
highly-loaded 5-ASA pellets by extrusion-spheronisation. Submitted for publication to Int. J. Pharm. 
 
Abstract 
 
The aim of the current work was to assess the feasibility of scaling-up, from a bench- 
to a pilot-scale extruder-spheroniser, a multiparticulate formulation containing a high 
load of 5-aminosalicylic acid (5-ASA). A preliminary study, aiming to compare the 
behaviour of 5-ASA-based pastes in a ram (bench-scale) and a basket (pilot-scale) 
apparatus was performed. Considered the complexity and multifactoriality of the E-S 
process, a factorial approach, namely a mixed fractional factorial design (MFFD) has 
been employed for the study. The influence of some process and formulation 
parameters on desired pellets characteristics, such as pellets size, size distribution, 
mechanical resistance, dissolution properties and process yield, was investigated. 
Moreover, an optimisation study, based on the desirability function approach, was 
performed to identify the combination of factors that would allow the optimal 
response values to be obtained. The possibility of scaling up a highly-5-ASA-loaded 
multiparticulate formulation from a bench to a pilot-scale apparatus was successfully 
demonstrated. The MFFD aided in the identification of the most affecting process 
and formulation variables. In addition, the optimisation study allowed the operative 
conditions for the obtainment of a multiple-unit dosage form, containing up to        
95 wt% 5-ASA, in a pilot-scale equipment, to be identified. 
 
Keywords: 5-aminosalicylic acid; extrusion-spheronisation; high drug loading; 
design of experiment; optimisation study. 
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1. ITRODUCTIO 
 
Inflammatory Bowel Disease (IBD) is a spectrum of chronic, episodic, inflammatory 
conditions of the gastrointestinal (GI) tract. IBD is conventionally divided into two 
major subtypes, i.e. Crohn’s disease (CD) and ulcerative colitis (UC). UC mainly 
affect the colon starting at the anal verge, even though it may extend proximally (e.g. 
colitis, left-side colitis and pancolitis). At converse, CD generally involves the small 
intestine and the ileocolonic area, with a variable extent. 
The current gold-standard molecule for the treatment of IBD (UC in particular) is    
5-aminosalicylic acid (5-ASA, mesalamine). As mesalamine is believed to act locally 
from within the gut lumen, prodrugs activated by colonic bacteria and oral modified 
drug delivery systems (DDS) are widely used to maximise deliver of 5-ASA to the 
target tissues, while minimising systemic absorption.  
Most of the mesalamine-based products, currently available on the market, are 
delayed-release DDS. They involve capsules and/or tablets coated with a polymeric 
film soluble over a certain value of pH (generally 7 since it is thought to be the pH 
value corresponding to the human terminal ileum). These delayed-release DDS might 
have important limitations. Firstly, pH is a highly-variable physiological parameter, 
in particular in those subjects suffering of IBD (Haddish-Berhane et al., 2006). 
Moreover, it has been demonstrated that delayed-release DDS are not equally 
effective in the treatment of both UC and CD, as they may not deliver therapeutically 
effective doses of 5-ASA to the small intestine and to the left side of the colon (a site 
predominantly affected in all patients with UC). Indeed, clinical studies have shown 
that mucosal 5-ASA concentrations using these formulations are typically highest in 
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the right-sided colon, whereas in the rectum the concentration of 5-ASA is much 
lower (Frieri et al., 1999). 
Another important limitation of the mesalamine-based products currently available 
on the market, is the relatively low dose of 5-ASA (generally 500 mg/unit). If 
considering in fact the complex IBD dosing regimen of 2.4-4.8 g/day, multiple daily 
administrations are required, thus reducing compliance and possibly compromising 
the therapeutic efficacy. 
Lately, new approaches to both simplify dose regimen and improve drug delivery to 
the affected areas of the GI tract have been investigated. These formulations are 
based on multiple-unit dosage forms (e.g. granules) opportunely coated to achieve a 
slow, and pH-independent, release of the active drug throughout the entire intestine. 
Multiparticulates may have several advantages over the standard, single-unit dosage 
forms, both from a biopharmaceutical (e.g. more even and predictable transportation 
in the GI tract) and a technological (e.g. high flexibility in tailoring the drug release) 
point of view. 
 
In our research project, highly-5-ASA loaded pellets were therefore sought as the 
drug core of a multi-particulate DDS with improved efficacy and compliance         
(Di Pretoro et al., 2010). Extrusion-spheronisation (E-S) was chosen as the 
manufacturing technique for pellet preparation since its claimed advantage to 
incorporate high levels of drug (Gazzaniga et al., 1998; Tomer et al., 2002). 
 
E-S formulations represent a complex systems, whose rheological behaviour is not 
yet fully understood and determined by both a number of particle-particle 
interactions and liquid phase phenomena (Wilson and Rough, 2006). Particle size, 
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morphology, packing behaviour and other related properties of solid components 
may dictate the rheological characteristics of such materials, in particular when the 
API represents the major component, by volume, of the paste formulation. 
In a previous work we studied, systematically, the rheological behavior of highly-
loaded 5-ASA pastes, using a bench-scale ram extruder (capillary rheometer, Zwick). 
We investigated the effect of chemical (acidity) and physical (particle size and 
shape) characteristics of 5-ASA on the E-S process of highly-API-loaded pastes, as 
well as the performance as E-S aids of a standard and colloidal MCC grades.  
Liquid phase migration (LPM), resulting in a non-uniform distribution of water 
within the extrudates and subsequent un-controlled agglomeration during 
spheronisation, was generally observed. The extent of LPM was demonstrated to be 
mainly dependent on the drug load and was identified as arising from the particle 
morphology (needle-like) of the API.  
Based on the results obtained we were able, by combining an accordingly modified 
grade of 5-ASA and colloidal MCC types, to develop a promising formulation for the 
obtainment of a multi-particulate dosage form containing up to 90 wt% 5-ASA. 
 
Being our next objective the realization of an industrial scalable multiple-unit dosage 
form, a feasibility study on the scale-up ability of both milling and E-S was 
performed. Firstly, in collaboration with a company specialised in milling processes 
(IMS Micronizzazioni S.p.A., Milano, Italy) we investigated the possibility of 
reproducing, by an industrial-scale microniser, a batch of 5-ASA with similar 
characteristics to those obtained via planetary ball-milling. Afterwards we 
investigated the feasibility of transferring the promising formulation, as identified in 
the ram extruder, to a pilot-scale apparatus (basket extruder, Nica® E-140). 
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E-S scale up is, in fact, a source of inconsistency between lab-scale results and 
industrial products. It is important to note that formulations which operate 
satisfactorily in one extruder type do not readily transfer to different machines 
(Newton et al., 1994). By changing extruder type different E-S products, in terms of 
density, particle size and size distribution, indeed, may be obtained. This is the 
reason why, when aiming to transfer a formulation, intended for E-S, from a bench- 
to a pilot-scale apparatus it is recommended to investigate again the influence of both 
the process and the formulation parameters on the new equipment. However, because 
of the complex nature of the E-S process and the high number of factors involved, it 
is not always possible to investigate systematically the effect of every single 
parameter.  
Experimental designs are therefore often employed, also in industrial scale-up, since 
they allow to evaluate the effect or “response” of many factors and levels with a 
reduced amount of trials and assist in estimating the main effects of each 
experimental factor on the product. In particular, factorial design type studies have 
proven useful in formulation development to understand the effect of variables and to 
control them to produce products having desired attributes (Zema et al., 2008). 
A mixed fractional factorial design, well suited for exploring both process and 
product variables and their interaction with each other, was therefore used in our 
study. A statistical approach was also employed to optimise final paste formulations, 
aiming to produce pellets containing the highest loading of 5-ASA possible. 
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2. MATERIALS AD METHODS 
 
2.1 Materials  
5-aminosalicylic acid (5-ASA) (Erregierre S.p.A., Bergamo, Italy) was used after 
micronisation. The colloidal Avicel® RC591 grade of microcrystalline cellulose 
(MCC) (IMCD S.p.A, San Donato Milanese, Italy) was used as the extrusion-
spheronisation aid in the experimental design. Another colloidal MCC grade (i.e. 
Avicel® CL611), and a standard one (i.e. Avicel® PH101) were also evaluated in 
preliminary trials. The primary liquid binder was water, with polyvinilpirrolidone 
(PVP K30) (BASF, Mount Olive, NJ, USA) and a low viscosity grade of 
hydroxypropyl methylcellulose (HPMC, Methocel® E5) (Colorcon, Inc. Harleysville, 
PA, USA) used as extra binders. 
 
2.2 Methods 
2.2.1 Micronisation 
The un-milled, commercial batch of 5-ASA was micronised in an air-jet mill 
apparatus (IMS Micronizzazioni S.p.A., Milano, Italy). The mill had a spiral 
chamber of 300 mm diameter. The milling gas was air. Due to secrecy agreements 
the operative conditions cannot be reported. 
 
2.2.2 Particle characterisation 
2.2.2.1 Particle size and shape measurements 
Particle size characterisation was performed by laser light scattering (Coulter LS 
230, Beckman Coulter Inc., Fullerton, CA, USA). Powder samples were sonicated 
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prior to analysis to break up potential aggregates. Data collected are reported in 
terms of volume-based relative size distribution.  
Particle shape, quantified in terms of aspect ratio (defined as minor axis/major axis) 
was determined by particle imaging device (Morphologi® G3, Malvern Instruments 
Ltd, Worcestershire, UK). At least 60,000 particles were analysed. Two-dimensional 
micrographs were also collected. 
 
2.2.2.2 Powder X-Ray Diffraction 
A Philips PW1050/25 diffractometer (Philips Analytical Inc., Natick, MA, USA) was 
used for powder x-ray diffraction (PXRD) analyses. Cu-Kα radiation (λ = 1.54 Å), 
generated with 30 kV and 15 mA, was used as the radiation source. Samples were 
packed in the same aluminum sample holder to promote reproducibility of 
conditions, taking care also to minimize preferred orientation effects. The operating 
conditions were as follows: scan speed 0.5° 2θ min-1; step size 0.02° 2θ; range        
5≤ 2θ ≤35°. 
 
2.2.2.3 BET surface measurements 
Surface area determination was performed by means of a SA3100 Surface Area 
Analyzer (Beckman Coulter, UK). According to the BET method, N2 was used as the 
adsorbate gas (USP 32 Physical Test. Specific Surface Area. Volumetric Method). 
Prior to surface area measurements, samples (approximately 2 g) were degassed at 
90°C under vacuum (0.4 Pa) for 1 h to remove physically adsorbed gases (water 
vapour). The measurement was carried out in triplicate. 
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2.2.3 Pellets preparation 
 
5-ASA and the E-S aid were dry blended in a Turbula® Shaker-Mixer T2F (Glen 
mills Inc., Clifton, NJ) for 10 minutes at 48 rpm. The powder mixture was 
transferred in a planetary mixer (Kenwood KM 010, Southampton, UK), assembling 
a K-shaped mixing arm, and the liquid binder slowly poured onto the bulk surface. 
The extra binder (PVP), when scheduled in the experimental design, was firstly 
dissolved in water and the resulting solution used for paste preparation. Granulation 
was performed at a constant speed of 250 rpm for 5 min. Pastes were stored for 24 h 
in airtight containers prior to extrusion to allow the water to equilibrate throughout 
the mixture. The batch size for each paste formulation was 1 Kg. 
The wet masses were extruded in a radial basket apparatus (Nica® model E140) 
equipped with a multi-holed screen (i.d holes= 1 mm; screen thickness= 1.25 mm;) 
and the resulting extrudates were then spheronised in a 64 cm diameter radial-hatch 
friction plate spheroniser (Nica® S320). All surfaces in contact with the paste were 
stainless steel. Pellets were dried in a vacuum oven at 40 °C for 24 hours. All 
experiments were performed at room temperature in an air-conditioned laboratory 
(21°C ± 2°C, humidity 20% ± 2%). 
 
2.2.4 Pellets characterization 
2.2.4.1 Sieve analysis 
The particle size distribution of pellets was estimated by sieve analysis (Octagon 
2000, Endecotts Ltd., UK; 5 minutes, amplitude 4) of approximately 100 g samples. 
ASTM standard sieves were used in the 250-1,400 µm range. Geometric mean 
diameter (dgeo) and geometric standard deviation (σgeo) were calculated from weight 
distribution of diameters. Process yield of the interesting size fraction (710-1,000 
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µm) was also calculated from the weight distribution. The product obtained, having a 
particle size less than 250 µm and above 1,400 µm were considered as the “fine” and 
the “coarse” fractions, respectively. 
 
2.2.4.2 Bulk density  
A sample weight (W) of about 50 g was poured into a 250 mL glass cylinder and the 
volume (V0) was determined. The bulk density was calculated as ρb = W/V0. The 
results presented are the mean of three replicates. 
 
2.2.4.3 Mechanical resistance 
Friability- Resistance of pellets to abrasion was evaluated through a procedure 
adapted from Ph. Eur. 6th Ed. “Friability of granules and spheroids-method B” 
(2.9.41). The oscillating apparatus was replaced with a horizontal oscillating mixer 
(Turbula®). About 10 g of pellets were placed in a 105 mL glass container along with 
20 glass spheres (7 mm diameter) and shaken for 10 minutes at 200 rpm. Loss of 
powder (< 250 µm) was determined and friability was calculated as the percent ratio 
between the amount of powder < 250 µm and the initial sample weight. 
Tensile strength- The mechanical characteristics of pellets were investigated using a 
texture analyzer (TA.HDPlus, Stable Micro Systems Ltd, Godalming, UK) after 
equilibrating the pellets at 20 °C and 20% relative humidity for at least 48 hours. The 
fracture force (F) of 50 pellets per batch at a loading rate of 0.1 mm/s was 
determined. To calculate the tensile strength (σ), the diameter (d) of each pellet in the 
crushing direction was considered (Equation 1). 
σ = 
2
6.1
d
F
∗
∗
π
 (1) 
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Both the friability and tensile strength tests were performed on the 710-1,000 µm 
granulometric fraction; non-spherical pellets were avoided for the calculation of the 
tensile strength to minimise errors. 
 
2.2.4.4 Pellets shape measurements  
Photomicrographs of pellets from the selected 710-1,000 µm size fraction were taken 
using a digital camera (Canon, J), linked to a stereomicroscope (Panagor, D). Images 
of about 300 pellets of every batch at a suitable magnification (1 pixel=10 µm) were 
translated into binary images. The images were analyzed by image analysis software 
(ImageJ) and the aspect ratio was calculated. 
 
2.2.4.5 Dissolution testing 
Dissolutions were performed in a USP 29 paddle apparatus (Dissolution System 
2100B, Distek, North Brunwick, NJ, USA) at the stirring rate of 100 rpm. Phosphate 
buffer (pH= 6.8 ± 0.05) (1,000 mL), thermostated at 37 ± 0.5 °C, was the dissolution 
medium. The sample amount used for analysis (1,000 mg) was adjusted to obtain 
sink conditions. Medium samples were automatically withdrawn at predetermined 
time points and spectrophotometrically analysed (Lambda 25, PerkinElmer, Monza, 
MI, I) at 230 nm. Each batch was analyzed in triplicates. The mean dissolution time 
(MDT) was calculated from the dissolution profile by Equation (2) (Costa et al., 
2001). 
 
MDT= 
∑
∑
=
=
∆
∆
n
j
j
n
j
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M
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ˆ
     (2) 
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where j is the sample number, n is the number of dissolution sample times, jtˆ is the 
time at midpoint between tj and tj-1 and ∆Mj is the additional amount of drug dissolved 
between tj and tj-1. 
 
2.2.5 Experimental design and Process Optimization 
 
A 3×24-1 mixed fractional factorial design was employed to investigate the effect of 
three formulation components (5-ASA:MCC ratio, PVP and water amount) and two 
process parameters (extrusion speed and spheronisation time) on the selected 
responses. In particular, the responses investigated were: pellets yield (710-1,000 
µm), fine (< 250 µm) and coarse (> 1,400 µm) fractions, particle size (dgeo) and size 
distribution (σgeo), particle shape (aspect ratio, AR), bulk density, mechanical 
resistance (friability and tensile strength) and dissolution properties (mean 
dissolution time, MDT). A total number of 27 experiments, including 3 replicates of 
the central point, to estimate the significance lack of fit tests, were performed. 
Statistical analysis was carried out using a software package (Statistica 7, StatSoft 
Inc., Tuls, OK).  
The least-squares method was used to estimate coefficients of successive 
polynomials. Adjusted R2 (R2adj) was calculated in order to evaluate the fitting of 
polynomials. F-statistic was used to identify statistically significant terms. 
Significant effects were evaluated by the analysis of variance at p < 0.05. Less 
significant regression coefficients were progressively eliminated to maximise the 
R
2
adj parameter. Moreover, an optimization step of both process and formulation 
parameters was performed by applying the desirability function approach (Derringer 
and Suich, 1980). 
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3. RESULTS AD DISCUSSIO 
 
3.1 Micronised 5-ASA preparation 
 
The physical characteristics, such as particle size and shape, of the active ingredients 
might be critical parameters when aiming to process, by E-S, high drug loadings. In 
the particular case of 5-aminosalicylic acid (5-ASA), the particle morphology 
(needle-like) was identified as the key factor in affecting the quality of extrudates, 
when 5-ASA-based pastes were processed by ram extrusion. In fact, liquid phase 
migration (LPM), resulting in a non-uniform distribution of water within the 
extrudates and subsequent un-controlled agglomeration during spheronisation, was 
generally observed (Di Pretoro et al., 2010). 
In a previous work we described a viable way of producing, via a bench-scale 
planetary ball-mill, a batch of 5-ASA with the appropriate characteristics of particle 
size and shape for ram extrusion of high (i.e. up to 90 wt%) 5-ASA loadings. 
However, even though planetary ball-milling is a highly efficient technique for fine 
grinding processing it may have few drawbacks, including potential contamination 
from the grinding media (e.g. balls), un-wanted mechanical activation, wide particle 
size distribution and low reproducibility of the product achieved. In cases where dry 
grinding, or a very narrow particle size distribution for the product, is needed, jet 
mills are preferred (Tuunila and Nyström, 1998). The jet mill is a static machine 
which does not have any grinding media. The grinding effect is produced mostly by 
inter-particle collision. Jet-milling have therefore several advantages over the ball-
milling technique, such as low product contamination, no heat build-up, narrow size 
distribution and, nearly-spherical uniform particle shape. 
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A systematic study was therefore performed in an industrial jet-mill apparatus 
(Chrispro® Jet-Mill, Micro-Macinazione S.A., Molinazzo di Monteggio, 
Switzerland), aiming to identify the operative conditions for the obtainment of a      
5-ASA batch, scalable to large-size plants and reproducible, with similar physical 
characteristics to those obtained via planetary ball-milling. Table 1.2 lists the results 
inherent to particle size and shape measurements for ball- and jet- milled products. 
The batch size of 5-ASA processed by air-jet milling was about 50 Kg in comparison 
to the barely 30 g of material processed via the bench-scale apparatus. 
 
Table 1.2: Particle size and shape data for ball- and jet-milled 5-ASA batches. Data inherent to ball 
milled 5-ASA are adapted from Di Pretoro et al., 2010. 
 
 
 
Both particle size and size distribution of ball- and jet-milled products are very 
similar, as evident from the d10, d50 and d90 values and confirmed by the specific 
surface area measurements. In addition, jet milling process was demonstrated to be 
as efficient as the ball-milling in changing the morphology of 5-ASA crystals. As 
evident from 2-D micrographs (Figure 1.2) and quantified by particle shape 
parameter (aspect ratio), the un-milled 5-ASA crystals are in fact rounded off after 
both jet- and ball-milling process. 
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Figure 1.2: Micrographs of (a) un-, (b) ball- and (c) jet-milled batches of 5-ASA (magnification 50×). 
 
 
 
Modification of the solid state on milling was also evaluated, by PXRD and DSC.  
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Figure 2.2: X-ray diffraction patterns for ball- and jet-milled batches of 5-ASA. Profile baselines are 
shifted for clarity. 
 
Figure 2.2 shows similar PXRD patterns for the two materials. The peak angular 
positions are in excellent agreement, indicating that milling did not affect the 
crystalline form of 5-ASA. Similarly, thermograms of all samples showed a single 
endothermic melting event at approximately 280 °C with a comparable associated 
enthalpy (about 980 J g-1).  
An industrial batch (50 Kg) of 5-ASA, with similar characteristics in terms of 
particle size and shape to those obtained via a bench-scale planetary mill, was 
therefore achieved. 
 
3.2 From bench-to-pilot scale extruder: preliminary settings 
 
Extrusion scale up is often a source of inconsistency between lab-scale results and 
industrial products (Newton et al., 1994). As mentioned, already, formulations which 
operate satisfactorily in one extruder type do not readily transfer to different 
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machines. Rheology of MCC-based pastes is strongly affected by the strain. 
Therefore, apparatus with different extrusion mechanisms and forces involved, may 
lead to products with different characteristics. For example, extruders based on a 
wiping action (e.g. screen extruders) provide low average shear rates followed by a 
rapid deformation, and hence the material is close to its yield stress during its 
processing. Radial extruders are therefore relatively insensitive to the solids particle 
size distribution in achieving good E-S products (Wilson and Rough, 2006). 
Conversely, in ram extruders low shear stresses are involved; this may lead to liquid 
phase migration phenomena, causing inconsistency in drug distribution within the 
dosage form as well as agglomeration of the pellets during E-S. Many approaches 
have been made to relate key deformation modes and rates in operation of lab- and 
pilot-scale extruders; Mascia (2009) demonstrated that paste properties vary 
significantly with strain rates and time scales of operation, which differ due to 
scaling between different extruders. By changing extruder type different E-S 
products, in terms of density, shape particle size and size distribution are therefore to 
be expected. 
As yet it is not possible to predict the behaviour of paste formulations when 
processed in different apparatus nor it is possible to relate the rheological properties 
of pastes directly to the tendency to form good quality E-S products. Therefore, when 
aiming to scale up a formulation, which operate satisfactorily in a bench-scale 
extruder, to a pilot-scale apparatus it is strongly recommended to valuate again the 
influence of all the formulation and process parameters. 
Basing on the above considerations, a set of extrusion trials was performed in 
a ram and a basket extruder apparatus, in order to compare the behaviour of the un-
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milled and micronised (ball- and jet-milled) batches of 5-ASA alongside the standard 
and the colloidal grades of MCC. The quality of the extrusion products was 
determined by monitoring, when feasible, the attitude of the extrudates undergoing 
spheronisation (800 rpm, 5 min). In table 2.2, the outcome of the E-S trials, are 
summarised.  
 
Table 2.2: Characteristics of E-S products obtained with ram and basket extruder apparatus, for the 
un-milled and micronised batches of 5-ASA (90 wt%) alongside three types of MCC. 
 
 
 
Un-milled 5-ASA: as previously demonstrated, when a high loading (90 wt%) of un-
milled 5-ASA was processed in ram extruder alongside Avicel PH101, acute liquid 
phase migration occurred, yielding an initial over-wet extrudate unsuitable for 
spheronisation and a dry immovable plug in the barrel that could not be extruded. 
This phenomenon is manly attributable to the high extrusion forces generated by the 
“pumping action” of ram extruder, but it is also arisen from the low water retention 
ability of Avicel PH101, as confirmed by previous studies (Podczeck et al., 2007). In 
fact, by replacing the standard MCC grade with colloidal ones (i.e. Avicel RC591 
and CL611), LPM was notably reduced, even though pellets obtained were far from 
being spherical (dumbbells shaped). Surprisingly, a similar outcome was achieved by 
processing the un-milled 5-ASA in the basket extruder, even though, contrary to 
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what observed in the ram apparatus, the un-milled 5-ASA/Avicel PH101 paste could 
be processed satisfactorily. This is most likely attributable to the ability of the wiping 
blades of basket apparatus to even out the pressure across the screen, which is in 
addition capable of flexing in response to the high stress involved. 
Micronised 5-ASA: the micronised batch of 5-ASA produced by industrial jet-mill 
apparatus was firstly processed in the bench-scale ram extruder, to compare its 
performance with that of the ball-milled material. A substantial similarity between 
the two micronised products was observed. In fact, once again, by reducing the drug 
particle size and modifying the morphology of 5-ASA crystals, LPM was notably 
decreased or eliminated and a high 5-ASA loading (90 wt%) could be successfully 
extruded. Similarities between the ball and the jet-milled materials, other than for 
their chemo-physical properties but also for they behaviour undergoing ram 
extrusion, was therefore demonstrated. 
 
The industrial jet-milled 5-ASA was afterwards tested in the pilot-scale basket 
extruder and its performance compared to that of the ram apparatus. 
Both in ram and basket extruders, jet-milled 5-ASA/Avicel PH101 pastes yielded a 
very dense extrudate, that did not have sufficient plasticity either to break up or to be 
rounded off within the spheroniser. However, increasing the moisture content in the 
paste formulation, to enhance plasticity, led to over wet-surface extrudates and 
resulted in uncontrollable agglomeration. Conversely, by replacing Avicel PH101 
with the colloidal ones, able to retain strongly water within their structure, plasticity 
was improved and good quality spheres where obtained. The best result, in ram 
extruder, was achieved by employing the MCC grade with the higher percentage in 
NaCMC, i.e. Avicel CL611. Conflicting results were obtained in the basket 
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apparatus. The best outcome (i.e. spherical pellets) was in fact achieved with Avicel 
RC591, whereas Avicel CL611 yielded both “spheres” and “rods”. 
 
The feasibility of processing high 5-ASA loadings in the basket extruder was 
assessed. Considered the complexity and the multifactoriality of the E-S process, an 
investigation of both formulation and process parameters, in the pilot-scale 
apparatus, was also performed. A factorial approach, namely a mixed fractional  
factorial design, was employed for this purpose. 
 
3.3 Preliminary trials: setting the experimental space 
 
Preliminary trials were performed to evaluate the most significant parameters and to 
establish their viable ranges for the experimental design (DOE). Since the colloidal 
Avicel RC591 grade of MCC yielded the most spherical pellets in basket extruder, it 
was selected as the E-S aid in the DOE. 
The formulation variables selected were: (1) 5-ASA loading, quantified as               
5-ASA:MCC ratio, (2) amount of water and (3) that of an extra binder (i.e. PVP). 
The process parameters were: extrusion speed and spheronisation time. 
As the objective of the present work was to assess the feasibility of preparing, in a 
pilot-scale apparatus, pellets containing the highest loading of 5-ASA possible, the 
low (-1) and high (+1) levels for the 5-ASA:MCC ratio investigated, were set in the 
DOE at 90:10 and 95:5, respectively. These values corresponded, in formulation 
where no extra binder was added, to a 5-ASA loading of 90 and 95 wt%, 
respectively. When the extra binder was added in paste formulation, these values 
corresponded to an actual 5-ASA loading of 88.2 and 93.1 wt%, respectively. 
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Water is known to be a critical variable in the E-S process. In fact, it acts as a binder 
during wet massing, a lubricant during extrusion and a plasticiser during 
spheronisation (Hileman et al., 1993). A careful choice of level values for this 
parameter is therefore necessary to obtain a wet mass with the appropriate degree of 
plasticity for extrusion and further spheronisation. An excess or, conversely, a lack of 
water added during paste formulation may result in severe over-wetted or dry 
masses, with consequent problems for extrusion and/or spheronisation. 
 
Expectedly, the effective water amount was found to be strictly depended on the      
5-ASA:MCC ratio. The optimal amount of water necessary to achieve a wet mass 
with a sufficient degree of plasticity, for each 5-ASA:MCC ratio, was therefore 
identified and set as the medium (0) level in the DOE. These values were then varied 
by ± 5 % to obtain the low (-1) and high (+1) levels for this variable. 
The spheronisation time was also found to be dependent on the 5-ASA:MCC ratio. In 
fact, with the amount of MCC in the formulation decreasing, the extrudate strength 
decreased and shorter spheronisation times were required. Preliminary trials were 
performed to detect the useful “spheronisation time” range for each 5-ASA:MCC 
ratio. The behaviour of extrudates undergoing spheronisation was monitored by 
visual inspection and the minimal and maximal spheronisation time determined 
accordingly to the behaviour of such materials. 
Since the amount of 5-ASA was increased up to 95 wt%, the influence of an 
extra binder on pellets characteristic was also considered. The performance of a low-
viscosity grade of hydroxypropyl methylcellulose (HPMC, Methocel® E5) and that 
of a polyvinyl pyrrolidone (PVP K30) were preliminarily compared. PVP was 
chosen over the other since it provided the best binding properties combined with 
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minimal sticking of extrudates during spheronisation. To avoid an excessive decrease 
of 5-ASA loading in the final paste formulation, PVP amounts ranging from 0 to 5 
wt% (dry mass), were considered. An amount of PVP equal to 2 wt% provided an 
acceptable balance between binding properties and minimal sticking; this amount 
was therefore set as the high level (+1) for the PVP amount in the experimental 
design, whereas no PVP was used when the low level (-1) was scheduled in the 
DOE. 
The NICA® radial screen extruder used in our study has two independently 
variable drives: the feeder drive which conveys the material into the extrusion zone 
and the extruder drive which forces the material through the screen. By varying the 
extrusion speed may result in different extrusion pressures and thereby in different 
pellet densification. At converse, the involvement of the feeder drive in the extrusion 
process is minimal. This was therefore set as a constant in the DOE (90 rpm, which 
corresponds to a mean value between the minimal and the maximal speed of the 
apparatus). The influence of the extrusion drive was, instead, investigated in the 
DOE. The low and high levels for the extrusion speed variable were set at 34 and 140 
rpm, respectively. These values corresponded to the lower and upper thresholds of 
the basket extruder. Along with the feeder speed, the spheroniser plate speed was 
also kept as a constant (800 rpm) in the DOE, in order to better investigate the 
influence of the other process parameters. Variables with their coded and actual 
values are summarised in Table 3.2. 
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Table 3.2: Coded and actual values for the factors used in the MFFD. Water and PVP amount 
depended on the 5-ASA:MCC ratio. Single (*) and double (**) asterisked values are relevant to those 
factors that depended on the 90:10 and 95:5 5-ASA:MCC ratio, respectively. 
 
LEVEL 
FACTOR 
-1 0 +1 
5-ASA:MCC ratio 90:10 - 95:5 
36.1* 38.0* 39.9* 
Water amount (w/w%, dry mass) 
33.3** 35.0** 36.8** 
PVP amount (w/w%, dry mass) 0 - 2 
Extrusion speed (rpm) 34 - 140 
5* - 10* 
Spheronisation time (min) 
2** - 5** 
 
 
3.4 Statistical optimisation study 
A 3×24-1 mixed fractional factorial design (MFFD) was employed to investigate the 
effects of the selected formulation (5-ASA:MCC ratio, water and PVP amounts) and 
operative (extrusion speed and spheronisation time) parameters on the process 
outcomes (yield and physico-technological properties of pellets). The MFFD 
responses defined were: particle size and size distribution (dgeo and σgeo), particle 
shape (aspect ratio), process efficiency (yield710-1,000µm, fine(<250µm) and coarse(>1,400µm) 
fractions), mechanical resistance (friability and tensile strength), bulk density and 
dissolution properties (mean dissolution time). Table 4.2 lists the experimental 
results relevant to the 27 trials performed.  
All but one batch (trial 5) were successfully manufactured. The trial 5 failed to be 
processed as the amount of water added accordingly to the DOE was not sufficient to 
provide a wet powder mass with the appropriate consistency for extrusion. Brittle 
extrudates, yielding a powdery material when subjected to spheronisation, were 
therefore obtained. 
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Process yield of the desired size fraction (710-1,000 µm) was generally satisfactory 
(> 70%). Only in two cases (trials 22 and 23) uncontrolled agglomeration of 
extrudates occurred and an excess of coarse (> 1,400 µm) product was obtained. 
Based on data reported in Table 4.2, the effect of factors (A, B, C, D and E) on the 
selected responses were calculated and statistically evaluated by the analysis of 
variance at p < 0.05. In Table 5.2 the regression and correlation coefficients as well 
as the ANOVA results for the MFFD are listed. The correlation between the selected 
factors and relevant responses was generally very good thus indicating the 
consistency of the approach (Table 5.2). The best fitting of data (R2adj > 0.9 and 
number of significant regression coefficients) was obtained for experimental data 
relevant to dgeo and σgeo. 
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Table 4.2: 3×24-1 MFFD: factors and response values. 
 
Factor  Response 
A B C D E            
Trial 
 
5-ASA:MCC 
ratio 
 
Water 
(wt%, dry 
mass) 
 
PVP 
(wt%, dry 
mass) 
 
Extrusion 
speed 
(rpm) 
 
Spheronisation 
time (min) 
 dgeo 
(µm) 
σgeo Aspect 
ratio 
Density 
(g/mL) 
Friability 
(%) 
Tensile 
strenght 
(N) 
MDT 
(min) 
Yield 
(%) 
Fine 
fraction 
(%) 
Coarse 
fraction 
(%) 
                 
1 90:10 36.10 2 34 5  958.7 1.3 1.5 1.0 2.9 12.2 22.0 76.7 0.1 9.4 
2 90:10 36.10 0 140 5  710.8 1.5 1.4 1.0 3.0 16.7 38.0 65.3 1.3 0.2 
3 90:10 36.10 0 34 10  711.6 1.7 1.4 1.0 5.0 28.2 54.9 71.0 4.8 0.1 
4 90:10 36.10 2 140 10  859.6 1.3 1.3 0.8 7.0 10.8 23.0 84.2 0.5 0.9 
5 95:5 33.25 0 34 2  - - - - - - - 0.0 100.0 0.0 
6 95:5 33.25 2 140 2  911.3 1.3 1.4 0.9 2.0 13.4 17.7 78.6 0.0 4.4 
7 95:5 33.25 2 34 5  731.7 1.6 1.3 0.9 3.0 19.5 19.4 69.1 4.1 0.6 
8 95:5 33.25 0 140 5  536.4 1.9 1.2 0.9 8.8 15.0 16.8 46.1 11.6 0.3 
9 90:10 38.00 2 34 5  963.2 1.2 1.4 0.8 1.0 15.1 20.6 83.9 0.1 4.6 
10 90:10 38.00 0 140 5  830.4 1.3 1.3 0.9 2.0 27.6 46.4 81.9 0.3 0.6 
11 90:10 38.00 0 34 10  767.1 1.5 1.4 0.9 1.0 24.8 49.6 73.2 2.2 0.2 
12 90:10 38.00 2 140 10  854.2 1.3 1.4 0.9 0.0 16.3 23.8 85.1 0.4 0.9 
13 95:5 35.00 0 34 2  861.0 1.5 1.3 0.8 1.9 19.7 20.1 67.3 2.0 6.9 
14 95:5 35.00 2 140 2  1257.4 1.2 1.4 0.8 1.0 14.5 15.3 27.6 0.0 61.5 
15 95:5 35.00 2 34 5  1135.3 1.3 1.4 0.9 1.0 14.9 33.5 42.0 0.1 41.9 
16 95:5 35.00 0 140 5  803.3 1.5 1.3 0.9 3.0 9.6 35.6 71.9 1.8 0.9 
17 90:10 39.90 2 34 5  1107.6 1.2 1.6 0.9 2.0 23.8 23.9 54.7 0.0 29.1 
18 90:10 39.90 0 140 5  911.3 1.2 1.4 0.9 1.0 19.7 43.0 85.0 0.0 1.9 
19 90:10 39.90 0 34 10  902.1 1.3 1.5 0.9 1.0 20.1 48.9 84.9 0.3 1.4 
20 90:10 39.90 2 140 10  1005.3 1.2 1.3 0.9 2.1 15.8 28.5 72.6 0.0 11.5 
21 95:5 36.75 0 34 2  1019.3 1.3 1.3 1.0 1.0 8.4 38.8 62.0 0.0 22.5 
22 95:5 36.75 2 140 2  1390.3 1.1 1.4 0.8 0.0 6.5 14.0 1.6 0.0 97.3 
23 95:5 36.75 2 34 5  1366.6 1.1 1.4 0.8 0.0 7.2 24.0 5.5 0.0 89.4 
24 95:5 36.75 0 140 5  963.5 1.3 1.3 0.8 2.9 3.2 42.2 78.3 0.1 6.0 
25 92.5:7.5 36.50 1 87 5.5  1097.4 1.2 1.4 0.8 0.9 17.8 32.1 56.2 0.0 26.4 
26 92.5:7.5 36.50 1 87 5.5  1113.5 1.2 1.3 0.8 1.0 17.8 33.5 52.4 0.0 30.3 
27 92.5:7.5 36.50 1 87 5.5  1110.4 1.2 1.3 0.8 0.9 17.8 33.0 54.2 0.0 40.1 
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Table 5.2: Regression and correlation coefficients for the 3×24-1 MFFD. Asterisks indicate significant 
p values (< 0.05). 
 
 
3.4.1 Pellet size and shape (dgeo, σgeo and aspect ratio) 
Narrow size distribution and spherical shape are amongst the claimed advantages of 
pellets prepared by extrusion-spheronisation. As widely described in literature, size 
distribution, dimension and shape of pellets are strictly related to both process and 
formulation parameters (Erkoboni, 2003). This was herein demonstrated; in fact all 
the formulation and process parameters investigated in the MFFD were identified to 
affect significantly both the size (dgeo) and the size distribution (σgeo) of pellets.  
Regression coefficient  
(p values, given in brackets) 
Polynomial 
term 
dgeo σgeo 
Aspect 
ratio Density Friability 
Tensile 
strenght MDT Yield 
Fine 
fraction 
Coarse 
fraction 
           
b0 
921.59* 
(0,00000) 
1.3578* 
(0,00000) 
1.3504* 
(0,00000) 
0.87275* 
(0,00000) 
1.3613* 
(0,00342) 
17.820* 
(0,00000) 
29.918* 
(0,00000) 
63.911* 
(0,00000) 
0.86177 
(0,07691) 
14.688* 
(0,00196) 
bA 
39.770* 
(0,00360) 
0.03224* 
(0,00354) 
-0.03482* 
(0,02271) 
-0.01474 
(0,10456) 
0.04366 
(0,85210) 
-3.3344* 
(0,00025) 
-5.2980* 
(0,00054) 
-12.639* 
(0,00007) 
0.69656* 
(0,02330) 
10.607* 
(0,00053) 
bB 
167.86* 
(0,00000) 
-0.16554* 
(0,00000) 
0.02049 
(0,24624) 
-0.03165* 
(0,00926) 
-1.6324* 
(0,00006) 
-1.8909* 
(0,03782) 
3.3270* 
(0,04124) 
-6.9845* 
(0,02561) 
-1.7951* 
(0,00017) 
16.221* 
(0,00010) 
bC 
123.50* 
(0,00000) 
-0.11658* 
(0,00000) 
0.02573 
(0,07953) 
-0.02068* 
(0,02842) 
-0.52950* 
(0,03792) 
-1.7523* 
(0,01927) 
-7.7820* 
(0,00001) 
-7.1031* 
(0,00699) 
-1.0877* 
(0,00159) 
13.619* 
(0,00007) 
bD 
-2.1034 
(0,85619) 
-0.03029* 
(0,00524) 
-0.03139* 
(0,03684) 
-0.02226* 
(0,01969) 
0.36134 
(0,14011) 
-1.8348* 
(0,01523) 
-1.2448 
(0,31260) 
0.94170 
(0,67849) 
-0.18648 
(0,49992) 
-0.13988 
(0,95040) 
bE 
-35.198* 
(0,00801) 
0.05340* 
(0,00008) 
-0.02877* 
(0,05293) 
0.00032 
(0,97058) 
0.52384* 
(0,03972) 
-0.47141 
(0,48136) 
3.4302* 
(0,01195) 
1.4202 
(0,53362) 
0.63693* 
(0,03502) 
-2.8316 
(0,22411) 
bB
2 - 0.02003 
(0,29173) 
0.03518 
(0,23572) 
0.02765 
(0,14160) 
1.5111* 
(0,00731) 
-2.8554 
(0,05576) 
- - 0.98896 
(0,10126) 
1.4786 
(0,75185) 
bAB 
82.158* 
(0,00005) 
-0.07083* 
(0,00005) 
- - - -3.3321* 
(0,00144) 
2.5278 
(0,10976) 
-6.9745* 
(0,02579) 
-1.0038* 
(0,01111) 
12.059* 
(0,00109) 
bCB - 
0.06544* 
(0,00009) 
- -0.01061 
(0,33310) 
- 1.5459 
(0,08062) 
-2.2816 
(0,14553) 
-14,794* 
(0,00014) 
1.2170* 
(0,00342) 
10.279* 
(0,00328) 
bDA 
17.774 
(0,14111) 
- 0.02164 
(0,13406) 
- - - - - - 2.2601 
(0,32592) 
bDB - 
0.01857 
(0,11746) 
- - - - - - - - 
bDC - - - - - - - - - - 
bDE 
-47.237* 
(0,00099) 
0.04281* 
(0,00047) 
- - 0.71283* 
(0,00806) 
-1.8469* 
(0,01470) 
-3.7985* 
(0,00646) 
6.7623* 
(0,00939) 
0.43591 
(0,12989) 
-9.2851* 
(0,00143) 
bEB - 
-0.04070* 
(0,00336) 
0.01763 
(0,31536) 
- -0.58763 
(0,06022) 
-1.5166 
(0,08580) 
- 3.3519 
(0,24808) 
-0.7648* 
(0,04136) 
-2.9214 
(0,31084) 
Correlation coefficient 
R2adj 0.93323 0.95979 0.48055 0.48707 0.74115 0.78769 0.48707 0.81323 0.76772 0.87065 
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Moreover, the ANOVA results shown in Table 5 indicate that the model proposed 
does have a very good fit for the data relevant to both dgeo and σgeo (R
2
adj > 0.9).  
 
Surprisingly, increasing the 5-ASA:MCC ratio in paste formulations, both dgeo and 
σgeo increased. MCC, in addition to other process and formulation parameters, plays 
in fact a key role in the water retention capacity of pastes, when subjected to pressure 
(e.g. extrusion). Once the MCC saturation threshold has been reached, the addition of 
extra water may lead to liquid phase migration (LPM), where the pressure on the 
liquid causes it to flow relative to the solids, leading to non-uniform extrudate water 
composition (Rough et al., 2002). Wet-surface extrudates (highly plastic and hence 
prone to agglomeration) and dry ones (contrariwise, not plastic enough to promote 
size enlargement) might be achieved. A batch of pellets constituted by both 
“aggregates” and “fines” may therefore be obtained and high σgeo values are hence to 
be expected. This is the reason why paste formulations containing the highest 5-ASA 
loading (5-ASA:MCC = 95:5) were found to be particularly sensitive to the amount 
of water added. In fact, satisfactory pellets could be obtained only at the low (-1) and 
intermediate (0) water levels, whereas at the high level (+1) LPM occurred. This was 
confirmed by monitoring the moisture content of extrudates at differing points during 
extrusion. With water and PVP amount in paste formulation increasing, the size of 
pellets increased, whereas the size distribution was narrowed down (σgeo decreased) 
(Fig. 3.2). Water and PVP, if exceeding a certain extent, might in fact enhance the 
plasticity/tackiness of the whole extrudate batch, thus promoting excessive size-
enlargement or uncontrolled agglomeration of pellets. The whole batch of pellets 
obtained will therefore be characterised by over-size and/or aggregates with a size    
> 1,400µm, whereas σgeo will be consequently low. 
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Figure 3.2: Effect of water and PVP amount on (a) dgeo and (b) σgeo. 
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The spheronisation time has been recognised by several co-workers as an important 
factor related to pellet dimension (Thommes et al., 2008). As expected, increasing 
the spheronisation time, the size of pellets decreased, whereas an increase in size 
distribution was observed. When undergoing spheronisation, the extrudates are in 
fact subjected to high mechanical stresses which may engender erosion phenomena 
and hence reduction of particle size and, conversely, increase of particle size 
distribution. 
 
The shape along with the particle size is an important characteristic for pellets, in 
particular when considering to perform a coating step for the achievement of the 
desired drug release performance. The shape of pellets is commonly described by the 
aspect ratio (AR). Among the formulation parameters, 5-ASA:MCC ratio influenced 
statistically the AR of pellets (Figure 4.2). Surprisingly, the most spherical pellets 
were obtained with the highest 5-ASA:MCC ratio (95:5). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Effect of 5-ASA:MCC ratio and extrusion speed on AR. 
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Other than the 5-ASA loading, the process parameters also affected markedly the 
shape of pellets. AR, indeed, decreased with the extrusion speed and the 
spheronisation time increasing. A higher spheroniser speed transfers, in fact, more 
energy to the extrudate batch, thus allowing more frequent breaking in the first phase 
and plastic deformation (Thommes et al., 2007). At higher extrusion velocities the 
extrudate surface presented in fact some superficial fractures (e.g. shark skin/cup-
shaped). These breaks allowed extrudates to break up into shorter cylinders, more 
easily to deform when subjected to spheronisation. Conversely, at lower extrusion 
velocities the extrudate surface was smoother and longer cylinders were formed. 
These cup-shaped fractures were more evident when 95:5 5-ASA:MCC paste 
formulations were extruded, in particular at high extrusion velocities. That is thereby 
the most likely reason why 95:5 5-ASA:MCC ratio paste formulations yielded the 
most spherical pellets. Moreover, as already demonstrated by several workers, e.g. 
Rough et al. (2005), cup-shaped fractures might help the extrudate to be fragmented 
into reproducible segments thereby helping to achieve a more narrow size 
distribution, other than improving sphericity of pellets. This was again demonstrated; 
increasing the extrusion speed allowed in fact the pellet size distribution to be 
narrowed down (< σgeo).  
Apart from the 5-ASA:MCC ratio, neither the formulation parameters nor interaction 
terms influenced significantly the shape of pellets. Therefore, the model proposed did 
not fit the data inherent to AR very well (R2adj < 0.5). This suggests the hypothesis of 
a more complicated relationship between variables and responses, that could not be 
determined by the fractional factorial design applied. 
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3.4.2 Process efficiency: (yield710-1,000µm, fine and coarse fractions) 
Process yield is a key issue to be considered when aiming to industrial scale-up. In 
addition, the batch of pellets produced should be both reproducible and have a very 
narrow size distribution. This is particularly important when aiming at the 
development of a modified (e.g. controlled- or delayed-release) multiple unit dosage 
form. Small differences in the particle size might correspond, in fact, to huge 
differences in terms of specific surface area, and hence release performance. For this 
reason we selected, as the desired process yield, a narrow granulometric fraction, i.e. 
710-1,000µm. 
Process yied710-1,000µm, fine(<250µm) and coarse(>1,400µm) fractions were significantly 
influenced by the formulation parameters. As already discussed in chapter 3.4.1, 
paste formulations containing a 5-ASA:MCC ratio equal to 95:5, were particularly 
sensitive to the amount of water added. Due to the low water retention capacity of 
pastes, LPM and hence non-uniform redistribution of liquid within the extrudates 
occurred, thus yielding both over-wet extrudates (and therefore over-size pellets) and 
dry ones (and hence a high percentage of fines). With the 5-ASA:MCC ratio 
increasing both the coarse and fine fraction therefore increased, whereas 
consequently the yied710-1,000µm decreased. 
Moreover, with water and PVP increasing in paste formulation, a statistically 
significant increase of the coarse fraction, whereas a decrease of both fine fraction 
and process yield were observed (Figure 5.2). 
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Figure 5.2: (a) Effect of 5-ASA:MCC ratio and PVP on process yield710-1,000µm and effect of water and 
PVP amounts on (b) fine and (c) coarse fractions. 
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As expected, the amount of fines was also influenced by the spheronisation time. 
When undergoing spheronisation, extrudates are in fact subjected to high mechanical 
stresses and subsequent possible erosion phenomena. 
In order to optimise the yield of the desired size fraction, while minimising unwanted 
formation of fines and/or overgrowth pellets, it is necessary to consider carefully 
both the amount of water an PVP added in paste formulation and the residence time 
of extrudates within the spheroniser. 
 
3.4.3 Mechanical properties: (friability and tensile strength) 
A high mechanical resistance is an important property of pellets, in particular when 
considering of further process steps, like drying and coating. 
Pellets friability was significantly influenced by the amount of water and PVP added 
in paste formulation. Expectedly, increasing these parameters the friability 
decreased. Both PVP and water promote, in fact, inter-particle binding and formation 
of a network of solid bridges (after solvent removal), thereby increasing the 
mechanical resistance of pellets. In point of fact, a deeper analysis of the quadratic 
term of water, suggests that the friability of pellets actually decreases when water is 
added within a certain experimental range, after which it starts increasing (Figure 
6.2). Moreover, the impact of water on pellets friability is more pronounced at low 
levels for this parameter. 
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Figure 6.2: Effect of water and PVP amount on friability. 
 
The spheronisation time also had a significant effect on pellets friability. Probably, 
the energy transferred to the extrudate batch increases, thus increasing the velocity of 
solvent removal from extrudates. The formation of liquid and solid (after drying) 
bridges is therefore less likely to happen thus decreasing the mechanical resistance of 
pellets. 
 
Ts, unlike friability, was also influenced markedly by the 5-ASA:MCC ratio. With 
this parameter increasing, Ts decreased (Figure 7.2). MCC confers, in fact, strength 
to extrudate and to pellet matrix. Paste formulations containing the lowest amount of 
MCC yielded therefore spheres with lower resistance. 
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Surprisingly, Ts decreased with the PVP amount in paste formulation increasing. 
Water also have a negative influence on pellets Ts; in reality, the quadratic term of 
water indicates that Ts increases when water is added within a certain experimental 
range, whereas from this point onward it starts decreasing. Therefore, water seems to 
improve the mechanical resistance of pellets only into a certain extent, analogously 
to what observed in the granulation process. 
 
Figure 7.2: Effect of water and 5-ASA:MCC ratio on Ts. 
 
The extrusion speed also has a statistically influence (negative) on the Ts of pellets. 
Lower extrusion velocities, by allowing a better packing of paste material, may in 
fact promote densification, thus increasing the mechanical strength of pellets. 
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3.4.4 Dissolution properties: (mean dissolution time) 
With respect to the biopharmaceutical performance of pellets, the dissolution 
properties were evaluated by the mean dissolution time (MDT). Both formulation 
and process parameters, but the extrusion speed, had a significant influence on the 
drug dissolution rate. 
Expectedly, MDT decreased with PVP in paste formulation increasing. PVP is in fact 
a water-soluble binder and thereby able to enhance the dissolution rate of drugs, in 
particular of sparingly soluble ones (Loftsson et al., 1999). The 5-ASA:MCC ratio 
also affected remarkably the drug dissolution rate. With 5-ASA:MCC ratio 
increasing, the mechanical resistance decreases, while the contact surface area 
between the API and the solvent increases, thus likely increasing the dissolution rate 
(Figure 8.2). 
 
 
 
Figure 8.2: Effect of PVP and 5-ASA:MCC ratio on MDT. 
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Both the water amount and the spheronisation time had a significant, positive effect 
on the drug dissolution rate. This agrees with the reduced mechanical resistance of 
pellets with such parameters increasing. This is therefore likely related to the 
increased porosity of the pellets batch produced. 
 
3.4.5 Pellets density 
Other than the high drug loading, another important characteristic of pellets we 
sought in our study, in respect to the aim of producing a high strength final dosage 
form, was a high bulk density value. 
The bulk density was found to be significantly affected by the amount of water and 
PVP, and by the extrusion speed parameters. As expected, with the extrusion speed 
increasing the bulk density decreased (Figure 9.2). In fact, lower extrusion velocities 
generally correspond to higher extrusion pressures, and hence greater densification of 
paste material. 
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Figure 9.2: Effect of water and extrusion speed on bulk density. 
 
Unexpectedly, with water and PVP amount in paste formulation increasing, pellets 
bulk density decreased. However, this may be attributed to a non uniform spherical 
shape of the pellets obtained when higher amount of either liquid or solid binders 
were used, since nearly spherical particles lead to higher bulk or tap density            
(L. Lachman, et al.,1986). 
However, the effect of formulation and process parameters on the product bulk 
density should be confirmed as the predictability of the model proposed is not 
satisfactory (R2adj < 0.5). 
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3.5 Optimisation study 
The goal of a design of experiments is to identify the combination of factors that 
would provide the optimal results to be obtained. With this aim, a desirability 
function approach was employed. Each response of the MFFD was therefore 
transformed into a dimensionless desirability scale (individual desirability, di). The 
individual desirability values were then combined using the geometric mean to give 
the overall desirability (D). For the calculation of D both Ts and MDT were 
excluded, since the results obtained for such parameters were already satisfactory in 
the whole experimental space. 
The following optimal combination of factor levels was achieved: (1) 5-ASA:MCC 
ratio, 90:10; (2) water amount, 37.1 wt%; (3) PVP amount, 0 wt%; (4) extrusion 
speed, 5.1 rpm; (5) spheronisation time, 2 min. 
 
As expected, the optimised formulation of pellets should contain the lowest amount 
of drug (5-ASA:MCC ratio = 90:10). However, since we demonstrated the 
possibility of producing satisfactory pellets also with the highest drug load, an 
additional optimisation study, was performed, setting the 5-ASA:MC ratio as a 
constant to 95:5. The new combination of factor levels achieved was: (1) water 
amount, 34.1 wt%; (2) PVP amount, 0 wt%; (3) extrusion speed, 45 rpm; (4) 
spheronisation time, 2 min. Three additional experiments, under these conditions, 
were performed to verify the predicted response and desirability values. Results are 
listed in Table 6.2. 
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Table 6.2: Predicted and experimental values for responses relevant to the trial performed under the 
optimal combination of factor values (water amount, 34.1 wt%; PVP amount, 0 wt%; extrusion speed, 
34 rpm; spheronisation time, 2 min) with 5-ASA:MCC ratio = 95:5. 
 
 
Relative error = [(predicted value-experimental value)/ predicted value]*100 
 
The values of the obtained responses and the calculated desirability of the new 
experiment were in good agreement with the predicted ones. 
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4. COCLUSIOS 
 
The feasibility of scaling-up a multiparticulate formulation, containing a high load of 
5-ASA, from a bench- to a pilot scale apparatus was successfully demonstrated. 
Firstly, the operative conditions for the production of an industrial batch of 5-ASA, 
with the appropriate characteristics of particle size and shape for extrusion of high 
API loadings, as previously identified in a bench-scale microniser, were found.  
To provide a high level of process understanding and control capability, a mixed 
fractional factorial design (MFFD) was employed to investigate the effect of some 
process and formulation variables on desired pellets characteristics, such as size, size 
distribution, mechanical resistance, process yield and dissolution properties. 
Moreover, an optimisation study based on the desirability function approach was 
employed to identify the operative conditions that would allow the optimal response 
values to be identified. 
The MFFD aided in investigating both process and formulation parameters that 
mostly affect the preparation of highly-loaded 5-ASA pellets in the pilot-scale 
apparatus. In addition, the statistical optimisation study allowed the operative 
conditions for the obtainment of pellets containing up to 95 wt% 5-ASA, and with 
good technological characteristics (e.g. mechanical resistance, size and shape), to be 
achieved
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HIGH STREGTH 5-ASA MULTIPLE-UIT DRUG DELIVERY 
SYSTEM (DDS): “PROPOSALS A:D PROSPECTS” 
 
 
1. OBJECTIVE 
 
The general aim of the research project has been the development of an oral drug 
delivery system (DDS) containing a high load (> 1,000 mg) of 5-aminosalicylic acid 
(5-ASA), in order to achieve a once/twice-a-day administration, thus improving 
compliance in inflammatory bowel disease (IBD). 
Multi-particulates (pellets) has been chosen for the development of the DDS, in 
virtue of both their technological (e.g. high drug loading and density) and 
biopharmaceutical (e.g. flexibility in tailoring drug release and even and predictable 
distribution along the gastrointestinal tract) advantages.  
As already and extensively discussed, 5-ASA is locally active and the location of the 
inflammation in IBD may vary and affect differing portions of the gastrointestinal 
(GI) tract, with predominance of the proximal intestine and ileocolonic region in the 
case of Crohn’s disease (CD) and distal areas of the large bowel in that of ulcerative 
colitis (UC). In order to meet all the potential IBD needs, a formulation able to 
deliver 5-ASA throughout the entire intestine would be thereby desirable. 
Nevertheless, the possibility to target specific GI regions, thus treating selectively 
differing IBD conditions, is also an important challenge and it will be topic of a 
further investigation. 
To obviate the high variability of pH along the GI tract, in particular in 
patients suffering of IBD, a drug release mechanism independent from pH should be 
seek. In addition, since 5-ASA is easily absorbed in the upper intestine (mainly in the 
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duodenum), drug release in the stomach should be avoided, thus maximising the 
therapeutic dose at the primary targets (lower in the small intestine and in the distal 
large bowel) while minimising risk of side effects. 
In the previous stages of the research project we demonstrated the feasibility of an  
E-S route for the preparation of highly-loaded 5-ASA pellets in a bench-scale 
apparatus [chapter 1] as well as the possibility of transferring the E-S formulation to 
a pilot-scale equipment [chapter 2]. On the basis of the experimental observations we 
are now able to produce pellets with a high drug loading (i.e. 95 wt% 5-ASA) and 
good technological properties (e.g. bulk density and mechanical resistance). 
 
The final stage of the research project was to evaluate the possibility of tailoring the 
5-ASA release profile accordingly to the specific IBD therapeutic needs. 
The first objective was the achievement of a prolonged, and pH-independent release 
of the API throughout the entire intestine. Therefore, 5-ASA pellets were coated with 
a polyvinyl acetate polymeric dispersion, to different theoretical weight gains. An 
additional enteric-coating polymeric layer was applied to avoid 5-ASA loss from 
pellets during the gastric residence time and allow drug release to start in the small 
intestine. 
Preliminary attempts to develop a final dosage form were also made. In this respect, 
multiparticulates are highly flexible systems since they can be easily dispensed into 
various dosage forms. Pellets may in fact be compressed into tablets or alternatively 
filled into capsules or sachets.  
Preliminary attempts to realise a final capsular dosage form were made. Capsules 
represent in fact a particular challenge when aiming to develop a high strength        
(> 1,000 mg) dosage form, since the limited volume available (max 1.38 mL, 000 
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size capsules). If a high strength formulation can be realised using capsules, it is 
therefore likely to be achieved with any of the other dosage forms above mentioned. 
 
To evaluate the release performance of the DDS under development, two commercial 
reference products were selected: LialdaTM, a single-unit high strength delayed-
release preparation (1,200 mg 5-ASA, tablets) and Pentasa®, a multiparticulate 
prolonged-release formulation (500 mg 5-ASA, capsules). 
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2. MATERIALS AD METHODS 
2.1 Materials 
5-aminosalicylic acid (5-ASA, mesalamine), was purchased from Erregierre S.p.A., 
(Bergamo, Italy) and used after micronisation (IMS Micronizzazioni S.p.A., Milano, 
Italy). The colloidal Avicel® RC591 grade of microcrystalline cellulose (MCC), 
employed as extrusion-spheronisation aid for pellets preparation, was donated by 
IMCD S.p.A (San Donato Milanese, Italy). Kollicoat® grades SR 30D and MAE 30DP, 
used for pellets coating, were a gift from BASF (Mount Olive, NJ, USA). Propylene 
glycol, potassium dihydrogen phosphate, potassium hydrogen phosphate, sodium 
chloride, sodium hydroxide and hydrochloric acid were all analytical grade and 
purchased from Sigma-Aldrich Chemie GmbH (Buchs, Switzerland). 
Two commercially available mesalamine-based products, i.e. LIALDATM (1,200 mg     
5-ASA, tablets) (Shire Pharmaceuticals Inc., Wayne, PA, USA) and Pentasa® (500 mg 
5-ASA, capsules) (Ferring Arzneimittel GmbH, Kiel), were purchased from local 
markets and used as reference preparations. 
 
2.2 Methods 
2.2.1 Pellets preparation 
5-ASA (95 wt%) and Avicel® RC591 (5 wt%) were dry blended in a Turbula® 
Shaker-Mixer T2F (Glen mills Inc., Clifton, NJ) for 10 minutes at 48 rpm. The 
powder mixture was transferred in a planetary mixer (Kenwood KM 010, 
Southampton, UK), assembling a K-shaped mixing arm, and water slowly poured 
onto the bulk surface. The wet masses were extruded in a radial basket apparatus 
(Nica® model E140) equipped with a multi-holed screen (i.d holes= 1 mm; screen 
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thickness= 1.25 mm;) at the extrusion speed of 34 rpm. The resulting extrudates were 
spheronised in a 64 cm diameter radial-hatch friction plate spheroniser (Nica® S320) 
for 2 minutes at 800 rpm. Pellets were dried in a vacuum oven at 40 °C for 24 hours. 
All experiments were performed at room temperature in an air-conditioned 
laboratory (21°C ± 2°C, humidity 20% ± 2%). A detailed discussion inherent the 
choice of process and formulation parameters as well as the technological 
characterisation of pellets can be found in chapter 2. 
 
 2.2.2 Coating of 5-ASA pellets 
5-ASA pellets of a size fraction 710-1,000 µm were selected for coating process. The 
pellet batch (300 g) was loaded into a fluidized bed apparatus, Glatt® GPCG-1 (Glatt 
Process Technology GmbH, Binzen, Germany), assembling a “bottom-spray” insert, and 
coating was performed accordingly to the different polymeric dispersions employed. The 
operative conditions are listed in Table 1.3. 
 
 - Kollicoat® SR 30D (KSR): the formulation of the polymeric dispersion used 
was: Kollicoat® SR 30 D, 50 wt%; 1,2 propylene glycol, 1.5 wt% (corresponding to 
10 wt% on the dry polymer); water, 48.5 wt%. The plasticiser was firstly dissolved in 
water; KSR was then added and the resulting dispersion stirred for 30 min prior to 
film coating. 5-ASA pellets were coated with KSR up to theoretical weight gains of 
2.5, 5, 7.5, and 10 %. The actual gains, determined by weighting pellets prior and 
after the coating process, were 1, 3, 5 and 7 w.g.%, respectively. 
 
 - Kollicoat
®
 MAE30 DP (KMAE): to avoid gastric breakdown of 5-ASA, an 
outer layer of an enteric coating polymer was applied. The formulation of the KMAE 
polymeric dispersion used was: Kollicoat® MAE30 DP, 58.5 wt%; 1,2 propylene 
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glycol, 2.6 wt% (corresponding to 14.8 wt% on the dry polymer); water, 38.9 wt%. 
5-ASA pellets, previously coated with KSR (5 w.g%) were further coated with 
KMAE up to theoretical weight gains of 5, 10 and 15 %. The actual gains determined 
were 3, 8 and 11 w.g.%, respectively. 
Film-coating with KMAE was also performed on the un-coated 5-ASA pellets, up to 
theoretical weight gains of 5, 10, 15 and 20 %, corresponding to the actual values of 
4, 8, 12 and 15, respectively. 
 
Table 1.3: Process parameters for Kollicoat® SR 30D and MAE 30 DP. 
PROCESS PARAMETER 
Kollicoat
®
 
SR 30D 
Kollicoat
®
 
MAE 30DP 
Inlet temperature (°C) 70 60 
Product temperature (°C) 40 50 
Air flow (m3/h) 100-120 80-100 
Nozzle internal diameter (mm) 1.2 1.2 
Spray pressure (bar) 1.8 1.5 
Spray rate (g/min) 12 18 
Curing 48h/ 40 °C 48h/ 40 °C 
 
 2.2.3 Drug release 
The USP dissolution methods for mesalamine-based products are different depending 
on whether they are prolonged- (pH 7.5, 8 h) or a delayed-release (pH 1.4/2h; pH 
6.0/1h; and pH 7.4/1.5 h) formulations. However, aiming to compare different 
products together, an alternative dissolution method proposed by Chuong et al., 
(2008) has been adapted in the current study study. A 12-h dissolution testing, based 
on three different buffer stages to simulate pH conditions of gastric, small and large 
intestinal fluids, was carried out. The dissolution media and operative conditions are 
reported in Table 2.3. 
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Table 2.3: Dissolution media and testing times used in the test. 
Buffer stage Medium pH value 
Testing time 
(h) 
I  HCl buffer 1.2 2 
II  Phosphate buffer 6.0 2 
III  Phosphate buffer 7.4 8 
 
Dissolutions were performed in a USP 29 paddle apparatus (Dissolution System 
2100B, Distek, North Brunwick, NJ, USA). The volume media was 1,000 mL (to 
keep sink conditions) at 37 ± 0.5 °C and a stirring rate of 100 rpm was employed. 
Medium samples were automatically withdrawn at predetermined time points and 
spectrophotometrically analysed (Lambda 25, PerkinElmer, Monza, MI, I) at λ= 303 
for the acidic stage (Abs= 1.8384[API] + 0.0669; R2=0.999) and λ= 330 nm for the 
buffer stages II and III (Abs= 0.0018[API] + 0.0648; R2=0.999). Data reported are 
the average of 6 determinations. 
 
The actual 5-ASA dose of un-coated and coated pellets was determined by dissolving 
an exactly weighted amount of pellets (̴ 1,000 mg) in 1,000 mL pH 7.4 phosphate 
buffer. The solution obtained was then spectrophotometrically analysed at λ= 330 
nm and the drug content thereby calculated by using the relevant calibration curve. 
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3. RESULTS AD DISCUSSIO 
 
5-ASA is a zwitterionic drug, with pKa values of 6.0, 3.0 and 13.9 corresponding to 
the NH3+, COOH and OH groups, respectively (Allgayer et al., 1985). The drug 
solubility is therefore pH-dependent. In Table 3.3 the solubility values of 5-ASA at 
pH 1.2, 6.0 and 7.4 are reported.  
 
Table 3.3: Solubility values of 5-ASA, determined experimentally at pH 1.2, 6.0 and 7.4. 
 
 
 
 
 
Being the API the major component by weight (95 wt%) of the multiparticulate 
formulation, the in-vitro dissolution performance of un-coated pellets is expected to 
be mainly influenced by the chemo-physical characteristics of the API. In Figure 1.3 
the dissolution release performance of highly-loaded 5-ASA pellets at pH 1.2, 6.0 
and 7.4 is shown. 
 
pH Solubility (g/L) 
1.2 (HCl buffer) 8.65 
6.0 (phosphate buffer) 4.15 
7.4 (phosphate buffer) 6.34 
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Figure 1.3: In-vitro mean (n=6) dissolution profiles of 5-ASA pellets (95 wt% 5-ASA, 5 wt% Avicel 
RC591) at pH 1.2, 6.0 and 7.4. Bars indicate standard deviation. 
 
Expectedly, the chemo-physical characteristics of the API influenced, in part, the 
drug dissolution performance of highly-loaded 5-ASA pellets. About 80 % of 5-ASA 
is in fact dissolved within about 30 min at pH 1.2 and 7.4, whereas it takes about 45 
min at pH 6.0. 
However, the overall dissolution performance seems to be mostly affected by the 
technological characteristics of pellets. The dissolution profile, at each pH condition, 
is in fact slightly slackened. This is most likely arisen from the high density, in terms 
of high particles packing, of pellets prepared by extrusion-spheronisation (E-S), in 
particular if compared to granules and/or to pellets obtained by different techniques 
(e.g. drug layering). In addition, the presence of insoluble fillers such as the 
microcrystalline cellulose (MCC), used as the E-S aid, might contribute to a “matrix-
like” release behaviour pellets. 
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3.1 Reference 5-ASA products: a comparative study 
The aim of our work was to tailor the drug release accordingly to specific IBD 
therapeutic needs. Two commercial mesalamine-based products, namely a high 
strength single-unit (LialdaTM) and a multiple-unit dosage forms (Pentasa®) were 
selected as reference formulations to our DDS. 
MMX mesalamine (1,200 mg 5-ASA, tablets), marketed as LialdaTM in the US and 
Mezavant TM in the EU (Shire Pharmaceuticals Inc., Wayne, PA, under license from 
Giuliani SpA, Milan, Italy), became after its introduction in the market in 2007 one 
of the most frequently prescribed products for the treatment of ulcerative colitis 
(UC). Another well-known mesalamine-based product is Pentasa®, a 
multiparticulate-based formulation available in capsule and tablet dosage forms (250 
and 500 mg 5-ASA) and, most recently, in sachets containing up to 1,000 mg API. 
Pentasa®, in contrast to LialdaTM and to other delayed-release systems, allows a 
prolonged-release of 5-ASA throughout the entire intestine to occur. For this reason 
Pentasa® is, to date, the only formulation used “off-label” to treat Crohn’s disease 
(CD) in addition to its indicated use in UC (Cohen R.D., 2006). 
The in-vitro drug release performance of LialdaTM and Pentasa® was tested in a III 
stages pH conditions (1.2, 6.0 and 7.4) to simulate gastric, small and large intestinal 
fluids (Figure 2.3). 
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Figure 2.3: In-vitro mean (n=6) dissolution profiles of LialdaTM (1,200 mg 5-ASA, tablets) and 
Pentasa® (500 mg 5-ASA, capsules). Dissolution test performed at pH 1.2 (2h), 6.0 (2h) and 7.4 (8h). 
Bars indicate standard deviation. 
 
 
As expected, no significant release of 5-ASA from LialdaTM tablets occurs under 
simulated gastric and small intestinal fluids condition, whereas almost the entire drug 
dose is released when the tablets approach a pH value > 7. Moreover a considerable 
variability of the time necessary for the polymeric film to dissolve and hence the 
tablet to start disintegrating, was observed (Figure 2.3). MMX technology consists in 
fact of a high strength mesalamine tablet coated with an acrylic-based resin (i.e. 
Eudragit® S), soluble at pH values exceeding 7. Such a pH-dependent mechanism 
may represent a limitation if considering the high variability of the above mentioned 
physiological parameter, in particular in subjects suffering of IBD. Moreover, the 
high drug dose is embedded in a single unit dosage form; this may represent a further 
limitation both from a safety (e.g. risk of dose dumping) and biopharmaceutical (e.g. 
distribution along the GI tract and drug release performance) point of view. 
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Based on the dissolution profiles obtained from LialdaTM tablets, the product appears 
to be more suitable for the treatment of distal IBD conditions, whereas it would not 
be expected to have any potential in the treatment of Crohn’s diseases and/or in 
pathological manifestations where the inflammation spreads over the small intestine 
(e.g. proximal colitis or pancolitis). LialdaTM, like most of the others delayed-release 
preparations, is indeed recommended for the treatment of distal IBD conditions, such 
as proctitis and distal UC. 
 
On the other hand, Pentasa® is a multi-particulate DDS based on 5-ASA granules 
enclosed within an ethylcellulose film, that should allow a sustained, pH-independent 
release of the API to occur. In sooth, the release rate of 5-ASA from Pentasa® 
granules at pH 1.2 is about six times higher than that of simulated small and large 
intestinal fluids (pH 6.0 and 7.4, respectively). This unexpected behavior was 
confirmed by other co-authors (e.g. Schellekens et al., 2007; Chuong et al., 2008) 
and was also observed for Pentasa® tablet and sachet dosage forms (Rudolph et al., 
2001; Schellekens et al., 2007). 
A substantial amount (> 50%) of 5-ASA was released from Pentasa® granules 
within the 2-h stay at pH 1.2. Such a considerable extent of drug released in the 
stomach would result in a relatively high loss of mesalamine, due to systemic 
absorption occurring in the duodenum, and subsequently to less drug reaching 
inflamed tissues lower in the small intestine and in the colon (Klotz et al., 1985; Vree 
et al., 2001). Another limitation of Pentasa® is the relatively low drug loading (500 
mg/unit), such to entail multiple daily administrations to meet the recommended drug 
dosage regimen (4.8 g/day 5-ASA).  
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However, Pentasa® is, to date, the only formulation that allows 5-ASA to be available 
within most of the GI tract, and that provides better release in the small intestine than 
other mesalamine-based preparations. For this reason Pentasa® is, as already 
discussed, the product of choice for the treatment of CD involving the small 
intestine. 
 
3.2 Tailoring the drug release 
Multiple unit systems offer the potential to easily modulate the drug release 
performance. Aiming to develop a final dosage form that would allow a slow, and 
pH-independent, release of the API throughout the entire intestine, 5-ASA pellets 
were coated with a polyvinyl acetate aqueous dispersion, i.e. Kollicoat® SR (KSR) 
up to theoretical weight gains of 2.5, 5, 7.5 and 10 %. The in-vitro dissolution 
profiles, performed at III buffer stages are shown in Figure 3.3. 
 
Figure 3.3: In-vitro mean (n=6) dissolution profiles of un-coated 5-ASA pellets (95 wt% 5-ASA,      
5 wt% Avicel® RC591) and release profiles of pellets coated with Kollicoat® SR up to theoretical 
weight gains of 2.5, 5, 7.5 and 10 %. Test performed at pH 1.2 (2h), 6.0 (2h) and 7.4 (8h). Bars 
indicate standard deviation. 
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The entire amount of 5-ASA from un-coated pellets is dissolved within the 2-h at pH 
1.2, as already shown in Figure 1.3.  
The release profile of pellets coated with KSR to a theoretical weight gain of 2.5 % is 
similar to that of the un-coated units, thus indicating the inability of the polyvinyl 
acetate dispersion to form a continuous film when applied at such small amount. 
Increasing by little the KSR to a theoretical weight gain of 5 %, a prolonged- and 
relatively pH-independent, release over the 12-h dissolution testing was achieved.  
Surprisingly, the release rate profile reached with such a small amount of KSR was 
already satisfactory to meet our needs, although the considerable amount (i.e. 36 %) 
of 5-ASA dissolved already at pH 1.2. 
 
As expected, by further increasing the amount of KSR up to theoretical weight gains 
of 7.5 and 10 %, the drug release rate was considerably decreased. The extent of the 
drug release rate reduction was excessive, relatively to our objectives. At the end of 
the 12-h dissolution testing, in fact, only about 30 % 5-ASA was released from 
pellets coated with KSR to a weight gain of 7.5 %, whereas less than 15 % 5-ASA 
from those coated with KSR up to 10 w.g.%. 
 
On the basis of the previous observations, pellets coated with KSR to a theoretical    
5 w.g.%, were selected for further studies. In particular, to minimise unwanted 
systemic absorption while maximising the therapeutic efficacy, an outer layer of a 
methacrylic acid/ethyl acrylate copolymer (i.e. Kollicoat® MAE 30 DP) up to 
theoretical weight gains of 5, 10 and 15 %, was applied to 5-ASA/KSR (5 w.g.%) 
coated pellets. The in-vitro mean dissolution profiles of 5-ASA/KSR (5 w.g.%) 
pellets coated with differing amount of KMAE are shown in Figure 4.3. 
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Figure 4.3: In-vitro mean (n=6) release profiles of 5-ASA pellets coated with Kollicoat® SR 
(theoretical weight gain 5%) and Kollicoat® MAE 30 DP up to theoretical weight gains of 5, 10 and 
15 %. Test performed at pH 1.2 (2h), 6.0 (2h) and 7.4 (8h). Bars indicate standard deviation. 
 
Kollicoat® MAE allowed a quite efficient in-vitro enteric protection to be achieved. 
In fact, an already small amount of KMAE (5 w.g.%) was able to reduce the amount 
of 5-ASA dissolved at pH 1.2 of about 22 %. By doubling the amount of KMAE   
(10 w.g.%) the drug amount dissolved was decreased of a further 9.5 %, whereas a 
complete enteric protection was reached by applying an amount of KMAE equal to 
15 w.g.%. 
 
Therefore, by combining a polyvinyl acetate (KSR) and an acrylate (KMAE) 
polymeric layers, to a theoretical weight gain of 5 and 15 %, respectively, the release 
profile of 5-ASA pellets was tailored accordingly to our objective.  
This formulation is in fact able, in-vitro, to avoid completely 5-ASA release at pH 
1.2. About 35 % of 5-ASA is released within the 2-h stay at pH 6.0, whereas the 
remaining dose of 5-ASA is then released at pH 7.4. 
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3.3 Final dosage form: proposals and prospects 
Multiparticulates are highly flexible systems, other than for the possibility they offer 
to easily modulate the drug release, also because they can be readily dispensed into 
various dosage forms. Pellets may in fact be compressed into tablets or alternatively 
filled into capsules or sachets. 
Regardless from the dosage form, an important characteristic of pellets to be 
considered when aiming to develop a high strength formulation is, along with the 
drug content, their bulk density value. 
In table 4.3, the bulk density values and theoretical 5-ASA contents of the highly-
loaded pellets, prior and after the film coating, are reported.  
 
Table 4.3: Bulk density values and theoretical 5-ASA contents of un-coated, KSR (5 w.g.%) and 
KSR/KMAE (5/15 w.g.%) coated pellets. 
 
Pellets 
5-ASA theoretical 
content (%) 
Bulk density 
(g/mL) 
Un-coated 95.0 0.86 ± 0.002 
KSR 5 w.g. % 90.4 0.90 ± 0.002 
KSR 5 w.g. % + KMAE 15 w.g. % 78.7 0.91 ± 0.004 
 
One of the main advantages of the extrusion-spheronisation technique is the 
possibility to produce pellets with a high drug loading and high density. This was 
herein demonstrated. In fact, the bulk density of the un-coated pellets is relatively 
high, in particular if compared to that of pellets prepared by other techniques and/or 
to granules. 
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Surprisingly, the application of a polymeric film increased (about 4 %) the bulk 
density of pellets. This may be attributable to an increased sphericity and surface 
smoothness, and hence to an improved flowability of the coated multiple units. 
As previously stated, a good bulk density value, along with a high drug loading, are 
important requirements when aiming to develop a high strength dosage form.  
Our multiparticulate system is able to meet both these requirements; a high strength 
drug delivery system (DDS), containing more than 1,000 mg 5-ASA is therefore 
likely to be achieved with any of the oral dosage forms proposed (i.e. capsules, 
tablets or sachets). 
 
A “worse case“ scenario, namely the development of a capsule dosage form, was 
preliminary considered for the multiple-unit DDS design. The largest capsules 
available for human use are, in fact, the 000 size, which have an overall capsule 
volume of 1.34 mL, corresponding to an actual available volume of approximately 
1.18 mL. 
At converse, the development of a high strength tablet dosage form would be 
relatively easier, as a consequence of bulk volume material reduction (and 
displacement of gaseous phase). A critical issue in this case would be, however, the 
protection of the functional coating when undergoing compression. 
The simplest possible way to achieve a high drug loading would be the 
development of a sachet dosage form. Considering in fact that about 3,000 mg pellets 
can be filled into a sachet, that would correspond to an actual 5-ASA dose/unit         
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Therefore, if a high strength preparation containing more than 1,000 mg 5-ASA can 
be realised using capsules, the feasibility with other dosage forms (i.e. tablets or 
sachets) is likely to be expected as well. 
 
Gelatine 000 size capsules (Capsugel Ltd., Bornem, BE) were filled, manually, with 
5-ASA pellets: 
1) un-coated, labelled F0 
2) coated with Kollicoat® SR (5 w.g.%, theoretical), labelled F1 
3) coated with Kollicoat® SR (5 w.g% theoretical) and Kollicoat® MAE (15 w.g.% 
theoretical), labelled F2 
The theoretical and actual 5-ASA contents was calculated on the basis of the net 
weight of capsules and the experimental content was also determined (Table 5.3). 
 
Table 5.3: Net weight of un-coated, KSR (5 w.g.%) and KSR/KMAE (5/15 w.g.%) coated pellets in 
000 size gelatine capsules (n=10). Theoretical 5-ASA content calculated as net of excipients used for 
pellet preparation and coating polymers. Experimental 5-ASA content determined at pH 7.4 phosphate 
buffer. 
 
5-ASA content (mg ± s.d.) 
Formulation Code 
Pellets  weight 
(mg ± s.d.) theoretical experimental ∆ %* 
Un-coated F0 1199 ± 1.73 1139 ± 0.981 1153 ± 1.12 + 1.18 
KSR 5 w.g. % F1 1237 ± 1.53 1113 ± 1.15 1135 ± 2.47 + 1.95 
KSR 5 w.g. % + 
KMAE 15 w.g. % 
F2 1253 ± 3.78 961.2 ± 1.22 1100 ± 3.04 + 12.6 
∗∆%= (experimental - theoretical)/ experimental*100 
 
The capsule filling with formulations was generally satisfactory. As expected from 
the bulk density values, listed in Table 4.3, the highest loadings were achieved with 
the KSR and KSR/KMAE coated pellets, thus confirming the ability of the film layer 
to increase the bulk density and improve the packing behavior of pellets. 
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The experimental 5-ASA content was always higher than the expectation, most likely 
because the coating weight gains were calculated on a theoretical basis. 
The actual 5-ASA contents (%) of F0, F1 and F2 preparations were also higher than 
those expected, i.e. 96.2, 91.8 and 87.8 %, respectively. 
The feasibility of preparing a high strength DDS, containing more than 1,000 mg    
5-ASA, in a capsule dosage form was therefore demonstrated. 
Prospects- To further increase the drug dose, alternative dosage forms will be 
evaluated. In particular, the possibility of realising tablets able to disintegrate 
promptly in the stomach, thus releasing the multiple-units will be assessed. 
Formulation strategies to protect the functionality of the polymeric layer (i.e. KSR 
and KMAE) undergoing compression will also be systematically investigated. 
 
The in-vitro dissolution performance of our multiple-unit DDS, namely to F1 and F2 
preparations, was compared to that of Pentasa® and LialdaTM (Figure 5.3). The         
5-ASA release rate (mg/h) from each formulation was also determined, by dividing 
the amount of 5-ASA released at each phase by the relative residence time (Table 
6.3). 
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Figure 5.3: Comparative mean (n=6) dissolution profiles of LialdaTM (1,200 mg 5-ASA, tablets), 
Pentasa® (500 mg 5-ASA, capsules), F1 (1,100 mg 5-ASA, capsules) and F2 (1,100 mg 5-ASA, 
capsules). Test performed at pH 1.2 (2h), 6.0 (2h) and 7.4 (8h). Bars indicate standard deviation. 
The overall dissolution profiles of F1 and Pentasa® seem to be quite similar. In 
reality, the release rate of the two preparation is comparable only at pH 7.4 (Table 
6.3). Under simulated gastric conditions, the amount of 5-ASA released from F1 is in 
fact about 1.4 times lower than that of Pentasa® granules, whereas in the simulated 
small intestine it is about 8 times higher.  
In addition, the release profile of F1 is notably less sensitive to pH changes than that 
of Pentasa® granules. 
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Table 6.3: Release rates of 5-ASA, during the III buffer stages, from Pentasa®, LialdaTM, F1 and F2 
(normalised to a dose of 500 mg). 
 
5-ASA release rate (mg/h per phase) 
 
I II III 
LialdaTM 9.50 10.0 57.6 
Pentasa® 130 7.50 26.6 
F1 91.3 57.0 21.2 
F2 0.10 89.8 33.8 
 
As expected from the dissolution profiles (Figure 4.3), the 5-ASA release from 
LialdaTM tablets was minimal in both the simulated stomach as well as conditions, 
whereas nearly the entire drug dose is released within the simulated large intestinal 
fluids. This is the reason why LialdaTM is useful in the treatment of distal IBD 
manifestations. As for Pentasa®, the drug release rate under simulated gastric 
conditions was about 5 times higher than in the large bowel and even 17 times higher 
than in the simulated small intestine. Moreover, the amount of 5-ASA released 
within the 2-h stay in the simulated small intestine is potentially minimal if aiming to 
treat proximal IBD manifestations. 
At converse, F1 preparation allows a considerable amount of 5-ASA to be released in 
the small intestine. An overall better release than that of the reference 
multiparticulate product was, therefore, achieved already without the application of 
an enteric coating polymer.  
However, with the additional enteric protection (F2) the in-vitro performance was 
notably improved. In fact, 5-ASA loss under simulated gastric condition was avoided 
and a continuous drug release throughout the entire intestine was achieved. 
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As stated before, an optimal mesalamine-based preparation, to meet different IBD 
needs should have some important characteristics: 1) a high strength (> 1,000 mg)   
5-ASA to achieve a once/twice daily administration, improving compliance; 2) 
prolonged-release mechanism to allow 5-ASA to be released throughout the entire 
intestine; 3) avoid/minimise drug release in the stomach to reduce risk of side-effects 
and maximise the therapeutic drug dose. 
We were therefore able to satisfy all the above mentioned requirements. 
 
 
 
 
References  
Allgayer H., Sonnenbichler J., Kruis W., Paumgartner G., 1985. Determination of the 
pK values of 5-aminosalicylic acid and N-acetylaminosalicylic acid and 
comparison of the pH dependent lipid-water partition coefficients of 
sulphasalazine and its metabolites. Arzneimittelforschung 35(9), 1457-1459. 
Chuong M.C., Christensen M.J., Ayres J.W., 2008. New dissolution method for 
mesalamine tablets and capsules. Diss. Tech. 15 (3), 7-13. 
Cohen R.D., 2006. Review article: evolutionary advances in the delivery of 
aminosalicylates for the treatment of ulcerative colitis. Aliment. Pharmacol. 
Ther. 24, 465-474. 
Klotz U. 1985. Clinical pharmacokinetics of sulphasalazine and 5-ASA. Clin. 
Pharmacokin. 10, 285–302. 
Rudolph M.W., Klein S., Beckert T.E., Petereit H., Dressman JB., 2001. A new 5-
aminosalicylic acid multi-unit dosage form for the therapy of ulcerative 
colitis. Eur. J. Pharm. Biopharm. 51(3), 183-90. 
Schellekens R.C., Stuurman F.E., van der Weert F.H., Kosterink J.G., Frijlink H.W., 
2007. A novel dissolution method relevant to intestinal release behaviour and 
its application in the evaluation of modified release mesalazine products. Eur. 
J. Pharm. Sci. 30(1), 15-20. 
High strength 5-ASA multiple-unit drug delivery system (DDS):  CHAPTER 3 
“proposal and prospects”  
__________________________________________________________________________________ 
 133 
Vree T.B., Dammers E., Exler P.S, Maes R.A., 2001. Multiple absorption patterns of 
mesalazine from two gastroresistant tablets in healthy male volunteers. Clin. 
Drug. Invest. 21, 295–305. 
 
  
 
 
 
 
 
 
 
 
COCLUSIOS
   Conclusions 
__________________________________________________________________________________ 
 134 
COCLUSIOS 
 
The aim of the research project was to develop an oral multiple-unit drug delivery 
system (DDS), containing a high dose of 5-aminosalicylic acid (5-ASA) for the 
treatment of inflammatory bowel disease (IBD). A DDS containing more than 1,000 
mg 5-ASA was sought to reduce frequency of administration, improving compliance. 
Multiparticulates were selected in virtue of their biopharmaceutical advantages, such 
as reduced risk of dose-dumping and more even distribution along the GI tract. 
Accordingly to specific IBD therapeutic needs, the DDS was intended to prevent 
gastric breakdown and allow a slow and pH-independent release of 5-ASA 
throughout the small and the large intestines to occur. 
 
The overall project has been divided into three stages: 
4) Development of a multiple-unit drug containing core, based on highly loaded 
5-ASA pellets [chapter 1]. 
5) Assessment of the scale-up ability of the promising highly-loaded multiple-
unit formulation [chapter 2]. 
6) Tailoring of drug release accordingly to specific IBD therapeutic needs, and 
proposal of a high strength multiple-unit drug delivery system (DDS) 
[chapter 3]. 
 
1) Firstly, the feasibility of  preparing pellets containing a high load of 5-ASA      
(i.e. > 90 wt%), by extrusion-spheronisation (E-S) technique, was assessed. The 
influence of the chemical (acidity) and physical (particle size and shape) 
characteristics of 5-ASA on the rheological behaviour of microcrystalline cellulose 
(MCC)-based pastes was systematically investigated using a bench-scale ram 
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extruder (capillary rheometer). Liquid phase migration (LPM) within the paste 
during the extrusion, and hence variation in water content of extrudates and 
reproducibility of the final E-S product, was generally observed. The extent of LPM 
was found to be related to both the drug loading and its physical properties. In 
particular, drug particle morphology (needle-like) was identified as the most critical 
parameter in the process. Therefore, a reduction in particle size, combined with a 
change in particle morphology, allowed LPM to be considerably reduced or 
eliminated. The effect of pH on MCC behaviour was, instead, found to be negligible.  
The performance of colloidal grades of MCC (Avicel RC591 and CL611) as 
alternative extrusion aids to the standard Avicel PH101 was also investigated: Avicel 
RC591 and CL611 proved to be superior aids for the highly-loaded 5-ASA pastes 
due to their ability to hinder water migration when subjected to pressure.  
Based on the results obtained, by combining an accordingly micronised API and 
colloidal MCC grade, a multiple-unit formulation containing not less than 90 wt% 5-
ASA could be developed. 
 
2) The possibility of scaling-up the promising multiple-unit formulation, identified in 
the bench-scale ram extruder, to a pilot-scale equipment (basket extruder) was 
afterwards assessed. Preliminary, the possibility of reproducing, by an industrial-
scale microniser, a batch of 5-ASA with physical characteristics (i.e. particle size and 
shape) to those obtained via a bench-scale apparatus (planetary ball-mill), was 
considered.  
To provide a high level of process understanding and control capability, a mixed 
fractional factorial design (MFFD) and a statistical optimisation approach were 
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employed in the study, to investigate the effect of some process and formulation 
variables on desired pellets characteristics (e.g. size and shape, size distribution, 
mechanical resistance, process yield and dissolution properties). 
The MFFD aided in investigating both process (extrusion speed and spheronisation 
time) and formulation (5-ASA:MCC ratio, water and extra binder amounts) 
parameters that significantly affect the preparation of highly-loaded 5-ASA pellets in 
the pilot-scale equipment. Moreover, the statistical optimisation study allowed a 
combination of process and formulation parameters for the obtainment of pellets 
containing up to 95 wt% 5-ASA, and with good technological characteristics (e.g. 
mechanical resistance, size and shape), to be obtained. 
 
3) Finally the feasibility of tailoring the drug release of highly-loaded 5-ASA pellets, 
accordingly to the specific IBD therapeutic needs, was undertaken. To achieve a 
modular sustained- and pH-independent release of 5-ASA, pellets were film-coated 
with a polyvinyl acetate polymeric dispersion up to different theoretical weight gains 
(w.g.%). A film thickness corresponding to a theoretical 5 w.g.%, was identified as 
being satisfactory to achieve a prolonged-release of 5-ASA within 12-h in-vitro 
dissolution testing, under simulated gastric (2-h), small (2-h) and large (8-h) 
intestinal fluid conditions. The in-vitro dissolution performance of the DDS was 
similar to that of a commercial reference multiparticulate product, i.e. Pentasa®   
(500 mg 5-ASA, capsules). 
Moreover, the application of an outer acrylate-based layer to a theoretical weight 
gain of 15 % allowed a complete enteric protection, and hence potential reduction of 
side-effects and improvement of therapy, to be achieved. 
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By combining a polyvinyl acetate and an acrylate-based polymeric layers, a 
multiparticulate formulation could be tailored accordingly to our objectives. 
First attempts to realise a high strength DDS in a capsule-dosage form, containing 
more than 1,000 mg 5-ASA, yielded satisfactory results. The multiple-unit 
preparation developed proved its superior in-vitro performance to that of the 
reference products tested. 
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FUTURE WORK 
 
The areas identified in this work as requiring further work are: 
 
i) To investigate the possibility of further increasing the 5-ASA dose/unit. 
Alternative dosage forms to capsules will therefore be considered. In 
particular, the feasibility of developing a high strength multiple-unit tablet 
dosage form, able to disintegrate in the stomach thus promptly releasing the 
multiparticulates, will be investigated. With this aim, technological strategies 
that would ease the tabletting process while protecting the functionality of 
polymeric layers (e.g. enteric- or sustained-release coatings) undergoing 
compression, will be evaluated. 
 
ii) To investigate alternative formulation strategies for 5-ASA delivery to 
specific areas of the GI tract. 
iii) To investigate the in-vivo release performance of the DDS.
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